<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Daily Briefing - February 02, 2026</title>
    <style>
        :root {
            --bg: #0d1117;
            --bg-secondary: #161b22;
            --bg-tertiary: #21262d;
            --text: #e6edf3;
            --text-secondary: #8b949e;
            --text-tertiary: #6e7681;
            --accent: #58a6ff;
            --accent-subtle: #388bfd26;
            --border: #30363d;
            --green: #3fb950;
            --green-subtle: rgba(63, 185, 80, 0.15);
            --yellow: #d29922;
            --yellow-subtle: rgba(210, 153, 34, 0.15);
            --red: #f85149;
        }

        @media (prefers-color-scheme: light) {
            :root {
                --bg: #ffffff;
                --bg-secondary: #f6f8fa;
                --bg-tertiary: #eaeef2;
                --text: #1f2328;
                --text-secondary: #656d76;
                --text-tertiary: #8b949e;
                --accent: #0969da;
                --accent-subtle: #0969da1a;
                --border: #d0d7de;
                --green: #1a7f37;
                --green-subtle: rgba(26, 127, 55, 0.12);
                --yellow: #9a6700;
                --yellow-subtle: rgba(154, 103, 0, 0.12);
                --red: #cf222e;
            }
        }

        * {
            box-sizing: border-box;
            margin: 0;
            padding: 0;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Noto Sans', Helvetica, Arial, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.6;
            padding: 0;
            min-height: 100vh;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            padding: 2rem 1.5rem;
        }

        header {
            margin-bottom: 2.5rem;
            padding-bottom: 1.5rem;
            border-bottom: 1px solid var(--border);
        }

        h1 {
            font-size: 1.75rem;
            font-weight: 600;
            margin-bottom: 0.25rem;
            letter-spacing: -0.02em;
        }

        .subtitle {
            color: var(--text-secondary);
            font-size: 0.95rem;
        }

        .stats {
            display: flex;
            gap: 1.5rem;
            margin-top: 0.75rem;
            font-size: 0.85rem;
            color: var(--text-secondary);
        }

        .stat-value {
            color: var(--text);
            font-weight: 600;
        }

        .nav-links {
            display: flex;
            gap: 1rem;
            margin-top: 1rem;
        }

        .nav-links a {
            color: var(--accent);
            text-decoration: none;
            font-size: 0.9rem;
        }

        .nav-links a:hover {
            text-decoration: underline;
        }

        /* Video Cards */
        .video-card {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 1.25rem;
            overflow: hidden;
            scroll-margin-top: 1rem;
        }

        .video-header {
            padding: 1.25rem 1.5rem 1rem;
        }

        .video-title {
            font-size: 1.05rem;
            font-weight: 600;
            margin-bottom: 0.6rem;
            line-height: 1.4;
        }

        .video-title a {
            color: var(--text);
            text-decoration: none;
            transition: color 0.15s ease;
        }

        .video-title a:hover {
            color: var(--accent);
        }

        .video-meta {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 0.6rem;
            font-size: 0.8rem;
            color: var(--text-tertiary);
        }

        .channel-info {
            display: inline-flex;
            align-items: center;
            gap: 0.45rem;
        }

        .channel-icon {
            width: 22px;
            height: 22px;
            border-radius: 50%;
            object-fit: cover;
            flex-shrink: 0;
            background: var(--bg-tertiary);
        }

        .channel-name {
            font-weight: 500;
            color: var(--text);
        }

        .channel-subs {
            color: var(--text-tertiary);
            font-size: 0.75rem;
        }

        /* Channel Pill */
        .channel-pill {
            display: inline-flex;
            align-items: center;
            gap: 0.4rem;
            background: var(--bg-tertiary);
            padding: 0.3rem 0.7rem 0.3rem 0.4rem;
            border-radius: 20px;
            font-size: 0.8rem;
        }

        .channel-pill .channel-icon {
            width: 20px;
            height: 20px;
        }

        .channel-pill .channel-name {
            font-weight: 500;
            color: var(--text);
        }

        .channel-pill .channel-subs {
            color: var(--text-tertiary);
            font-size: 0.7rem;
            margin-left: 0.15rem;
        }

        /* Tags */
        .video-tags {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin-top: 0.6rem;
        }

        .tag {
            display: inline-block;
            background: var(--accent-subtle);
            color: var(--accent);
            padding: 0.2rem 0.6rem;
            border-radius: 12px;
            font-size: 0.72rem;
            font-weight: 500;
        }

        .tag-person {
            background: rgba(136, 87, 255, 0.15);
            color: #a371f7;
        }

        @media (prefers-color-scheme: light) {
            .tag-person {
                background: rgba(130, 80, 223, 0.12);
                color: #6639ba;
            }
        }

        .channel-badge {
            background: var(--accent-subtle);
            color: var(--accent);
            padding: 0.2rem 0.55rem;
            border-radius: 4px;
            font-size: 0.75rem;
            font-weight: 500;
        }

        .high-trust-badge {
            background: var(--green-subtle);
            color: var(--green);
        }

        .meta-sep {
            color: var(--border);
        }

        /* TL;DR Section */
        .tldr {
            padding: 0.9rem 1.5rem;
            background: var(--bg-tertiary);
            border-top: 1px solid var(--border);
            font-size: 0.9rem;
            color: var(--text-secondary);
            line-height: 1.55;
        }

        /* Summary Section */
        .summary-section {
            padding: 1rem 1.5rem 1.25rem;
            border-top: 1px solid var(--border);
        }

        .summary-preview {
            font-size: 0.92rem;
            line-height: 1.7;
            color: var(--text);
        }

        .summary-full {
            display: none;
            font-size: 0.92rem;
            line-height: 1.7;
        }

        .summary-full.expanded {
            display: block;
        }

        .summary-full h3 {
            font-size: 0.95rem;
            font-weight: 600;
            color: var(--text);
            margin: 1.25rem 0 0.6rem;
        }

        .summary-full h3:first-child {
            margin-top: 0;
        }

        .summary-full h4 {
            font-size: 0.9rem;
            font-weight: 600;
            color: var(--text);
            margin: 1rem 0 0.4rem;
        }

        .summary-full ul {
            margin: 0.4rem 0;
            padding-left: 1.3rem;
        }

        .summary-full li {
            margin: 0.35rem 0;
        }

        /* Nested lists - indentation only, no color/size change */
        .summary-full ul ul {
            margin: 0.2rem 0;
        }

        .summary-full ul ul li {
            margin: 0.25rem 0;
        }

        .summary-full strong {
            color: var(--text);
            font-weight: 600;
        }

        .summary-full p {
            margin: 0.6rem 0;
            line-height: 1.65;
        }

        .summary-full blockquote {
            margin: 1rem 0;
            padding: 0.75rem 1rem;
            background: var(--bg-tertiary);
            border-left: 3px solid var(--accent);
            border-radius: 0 6px 6px 0;
            font-style: italic;
            color: var(--text-secondary);
        }

        .summary-full em {
            font-style: italic;
        }

        /* Toggle Buttons */
        .toggle-btn {
            background: none;
            border: none;
            color: var(--accent);
            padding: 0;
            font-size: 0.85rem;
            font-weight: 500;
            cursor: pointer;
            margin-top: 0.6rem;
            display: inline-flex;
            align-items: center;
            gap: 0.3rem;
            transition: opacity 0.15s ease;
        }

        .toggle-btn:hover {
            opacity: 0.8;
        }

        .toggle-btn svg {
            width: 16px;
            height: 16px;
            transition: transform 0.2s ease;
        }

        .toggle-btn.expanded svg {
            transform: rotate(180deg);
        }

        /* Transcript Section */
        .transcript-section {
            padding: 0 1.5rem 1.25rem;
        }

        .transcript-toggle {
            background: var(--bg-tertiary);
            border: 1px solid var(--border);
            color: var(--text-secondary);
            padding: 0.5rem 0.9rem;
            border-radius: 6px;
            font-size: 0.8rem;
            font-weight: 500;
            cursor: pointer;
            transition: all 0.15s ease;
        }

        .transcript-toggle:hover {
            background: var(--border);
            color: var(--text);
        }

        .transcript-content {
            display: none;
            margin-top: 0.75rem;
            padding: 1rem;
            background: var(--bg);
            border-radius: 6px;
            font-size: 0.85rem;
            line-height: 1.75;
            white-space: pre-wrap;
            max-height: 400px;
            overflow-y: auto;
            border: 1px solid var(--border);
            color: var(--text-secondary);
        }

        .transcript-content.expanded {
            display: block;
            animation: fadeIn 0.2s ease;
        }

        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }

        /* Empty State */
        .empty-state {
            text-align: center;
            padding: 4rem 2rem;
            color: var(--text-secondary);
        }

        .empty-state h2 {
            font-size: 1.2rem;
            margin-bottom: 0.4rem;
            color: var(--text);
        }

        /* Index Page Styles */
        .day-list {
            list-style: none;
        }

        .day-card {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 1rem;
            overflow: hidden;
            transition: border-color 0.15s ease;
        }

        .day-header-link {
            display: block;
            padding: 1.25rem 1.5rem 0.75rem;
            text-decoration: none;
            color: inherit;
        }

        .day-header-link:hover .day-date {
            color: var(--accent);
        }

        .day-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .day-date {
            font-weight: 600;
            font-size: 1rem;
            color: var(--text);
            transition: color 0.15s ease;
        }

        .day-count {
            color: var(--text-tertiary);
            font-size: 0.85rem;
        }

        .day-previews {
            display: flex;
            flex-direction: column;
            padding: 0 1.5rem 1rem;
        }

        .day-preview-item {
            display: flex;
            flex-direction: column;
            gap: 0.3rem;
            padding: 0.6rem 0;
            border-bottom: 1px solid var(--border);
            text-decoration: none;
            color: inherit;
            border-radius: 4px;
            transition: background 0.12s ease;
        }

        .day-preview-item:hover {
            background: var(--bg-tertiary);
        }

        .day-preview-item:last-child {
            border-bottom: none;
            padding-bottom: 0;
        }

        .preview-title {
            font-size: 0.88rem;
            font-weight: 500;
            color: var(--text);
            line-height: 1.35;
        }

        .preview-meta {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 0.4rem;
            font-size: 0.75rem;
            color: var(--text-tertiary);
        }

        .preview-pill {
            display: inline-flex;
            align-items: center;
            gap: 0.3rem;
            background: var(--bg-tertiary);
            padding: 0.15rem 0.5rem 0.15rem 0.25rem;
            border-radius: 14px;
        }

        .preview-channel-icon {
            width: 14px;
            height: 14px;
            border-radius: 50%;
            object-fit: cover;
            flex-shrink: 0;
        }

        .preview-channel-name {
            font-weight: 500;
            color: var(--text-secondary);
            font-size: 0.72rem;
        }

        .preview-channel-subs {
            color: var(--text-tertiary);
            font-size: 0.68rem;
        }

        .preview-details {
            font-size: 0.72rem;
            color: var(--text-tertiary);
        }

        .preview-tags {
            display: inline-flex;
            gap: 0.3rem;
        }

        .tag-sm {
            padding: 0.1rem 0.45rem;
            font-size: 0.65rem;
        }

        .preview-tldr {
            font-size: 0.78rem;
            color: var(--text-tertiary);
            line-height: 1.45;
        }

        footer {
            margin-top: 3rem;
            padding-top: 1.5rem;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-tertiary);
            font-size: 0.8rem;
        }

        /* Mobile Adjustments */
        @media (max-width: 600px) {
            .container {
                padding: 1.25rem 1rem;
            }

            .video-header, .tldr, .summary-section, .transcript-section {
                padding-left: 1rem;
                padding-right: 1rem;
            }

            .video-title {
                font-size: 1rem;
            }

            .transcript-content {
                max-height: 300px;
            }
        }
        </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Daily Briefing</h1>
            <p class="subtitle">February 02, 2026</p>
            <div class="stats">
                <span><span class="stat-value">5</span> videos</span>
            </div>
            <nav class="nav-links">
                <a href="index.html">&larr; All Briefings</a>
            </nav>
        </header>

        <main>
            
            <article class="video-card" id="video-0">
                <div class="video-header">
                    <h2 class="video-title">
                        <a href="https://www.youtube.com/watch?v=7SBWYjtIKTI" target="_blank" rel="noopener">Jason Trennert on Populism, Policy &amp; a Distorted Market System | The Real Eisman Playbook Episode 44</a>
                    </h2>
                    <div class="video-meta">
                        <span class="channel-pill"><img class="channel-icon" src="https://yt3.ggpht.com/K8ArKyY9V68hNXTvV9Tbzg2WMgOyH48-T7QmkV4Sct68oETra0imiCpwbNqrC5Bp_k3nXrxI=s240-c-k-c0x00ffffff-no-rj" alt="" loading="lazy"><span class="channel-name">Steve Eisman</span><span class="channel-subs">(148.0K)</span></span>
                        <span class="meta-sep">·</span><span>48:46</span>
                        <span class="meta-sep">·</span><span>33.6K views</span>
                        <span class="meta-sep">·</span>
                        <span>2026-02-02</span>
                    </div>
                    
                </div>
                <div class="tldr">Populism is driving a new economic phase marked by higher inflation and robust nominal growth, favoring hard assets and specific sectors like industrials.</div>
                <div class="summary-section">
                    <div class="summary-preview" id="preview-0">Populism is driving a new economic phase marked by higher inflation and robust nominal growth, favoring hard assets and specific sectors like industrials. While the public market is expensive due to Fed backstops, significant risks are accumulating in opaque private markets, and...</div>
                    <div class="summary-full" id="full-0">
                        <h3>TL;DR</h3>
<p>Populism is driving a new economic phase marked by higher inflation and robust nominal growth, favoring hard assets and specific sectors like industrials. While the public market is expensive due to Fed backstops, significant risks are accumulating in opaque private markets, and new investment frontiers are emerging in AI and prediction markets.</p>
<h3>The Economic Landscape &amp; Populist Drivers</h3>
<ul>
<li><strong>Strong 2026 Economic Outlook:</strong> The economy is projected to be strong, making a recession unlikely.</li>
<ul>
<ul>
<li><strong>Catalysts:</strong> A "One Big Beautiful Bill" is expected to inject approximately <strong>$150 billion</strong> into the system through tax refunds and stimulus.</li>
<li><strong>Supply-Side Boosts:</strong> Provisions for increased capital spending allow immediate write-offs for building new plants.</li>
<li><strong>National Events:</strong> The 250th anniversary of the country and the World Cup in the US will further stimulate economic activity.</li>
<li><strong>Forecast:</strong> Earnings growth is anticipated at <strong>14-15%</strong>, and GDP at <strong>3%</strong> (plus <strong>2.5%</strong> inflation) yields <strong>5.5%</strong> nominal growth.</li>
<li><strong>Sustainability Question:</strong> Long-term sustainability beyond 2026-2027 will depend on the success of these capital investments.</li>
</ul>
</ul>
<li><strong>Populism's Deep Roots:</strong> Populism has dominated the American political scene for the last decade, stemming from public dissatisfaction with social and economic experiments that haven't improved lives.</li>
<ul>
<ul>
<li><strong>Trade &amp; Jobs:</strong> "Free trade" with countries fixing their currency (e.g., China) benefited big businesses but not average people, who prioritize jobs over cheaper goods.</li>
<li><strong>Immigration:</strong> Uncontrolled immigration is a significant concern for both economic (jobs) and cultural reasons.</li>
<li><strong>Environmental Policy:</strong> The environmental movement, particularly in Europe, "got out of hand" with unrealistic mandates (e.g., auto manufacturers backtracking on EV plans); fossil fuels remain essential for global energy access.</li>
</ul>
</ul>
<li><strong>Tariffs as Negotiation Tactics:</strong> President Trump's tariff threats (e.g., <strong>200%</strong> on French wine) are viewed as part of a continuous "negotiation process."</li>
<ul>
<ul>
<li><strong>Greenland &amp; Rare Earths:</strong> Greenland's rare earths are highlighted for their national security importance, especially for AI and economic growth, which the US could potentially acquire without purchase.</li>
</ul>
</ul>
<li><strong>Investment Implications of Populism:</strong></li>
<ul>
<ul>
<li><strong>Higher Inflation:</strong> Expect higher inflation due to increased government spending aimed at public appeasement.</li>
<li><strong>Sector Focus:</strong> Industrials, materials, and hard assets (gold, farmland) are expected to outperform as hedges against inflation.</li>
</ul>
</ul>
</ul>
<h3>The Fed, Public Markets, and Investor Behavior</h3>
<ul>
<li><strong>Expensive Public Markets:</strong> The market is currently "expensive" by historical standards, with valuations (P/E, P/B, P/CF) in the "top couple of percent" of all-time readings.</li>
<ul>
<ul>
<li><strong>AI Justification:</strong> While AI is a "game-changing technology" that offers some justification, other factors contributing to high valuations are considered "not so great."</li>
</ul>
</ul>
<li><strong>Negative Consequences of Quantitative Easing (QE):</strong> An inflated Federal Reserve balance sheet and the Fed's consistent willingness to "backstop problems" (financial repression) are key drivers of current market expense.</li>
<ul>
<ul>
<li><strong>Financial Engineering:</strong> QE encourages companies to prioritize stock buybacks over real capital investments, as low interest rates make issuing bonds for buybacks more attractive than building plants.</li>
<li><strong>Distorted Capital Formation:</strong> Funds flow into companies that might not otherwise be viable, creating issues like private equity firms holding unsellable assets.</li>
<li><strong>Enabling Fiscal Irresponsibility:</strong> The Fed's role in monetizing debt allows politicians to "spend whatever they want," with a notable "lack of sophistication" in Washington regarding the national debt.</li>
<li><strong>Moral Hazard:</strong> Constant backstopping (e.g., Silicon Valley Bank) reduces market discipline, fostering a belief among investors that the Fed will intervene in a crisis.</li>
</ul>
</ul>
<li><strong>Institutional Investor Sentiment:</strong> Institutional investors are "cautiously optimistic" and "fully invested," particularly in growth stocks, despite acknowledging underlying risks.</li>
<li><strong>Rise of Retail &amp; Meme Stock Power:</strong> The influence of retail investors has dramatically increased due to fewer publicly traded companies, online/commission-free brokerages, and rapid information sharing.</li>
<ul>
<ul>
<li><strong>Consequence:</strong> This environment can make investing "akin to gambling," often sidelining long-term investment strategies.</li>
</ul>
</ul>
</ul>
<h3>Unseen Risks in Private Markets</h3>
<ul>
<li><strong>The Illusion of Low Volatility:</strong> Institutions (e.g., pension funds, endowments) are attracted to private equity (PE) by its reported low volatility, largely because assets are "marked once a month" by the PE firms themselves ("marked to private equity").</li>
<ul>
<ul>
<li><strong>Underlying Reality:</strong> Despite the lack of daily price fluctuations, these highly leveraged private investments inherently carry "much higher" volatility, which simply remains unobserved.</li>
</ul>
</ul>
<li><strong>Drivers of PE Investment:</strong></li>
<ul>
<ul>
<li><strong>Unrealistic Return Targets:</strong> State pension plans, facing balanced budget requirements, often mandate "7%" returns when realistic projections might be "5%", pushing them into PE to bridge the gap and avoid benefit cuts or tax increases.</li>
<li><strong>Uninformed Wealthy Investors:</strong> Many affluent investors are unaware of the "extraordinary" fees associated with private equity.</li>
</ul>
</ul>
<li><strong>Current Challenges:</strong></li>
<ul>
<ul>
<li><strong>Inter-firm Transactions:</strong> A significant portion (<strong>60-65%</strong>) of all PE transactions are between PE firms themselves, raising questions about genuine value creation.</li>
<li><strong>Stagnant Exits:</strong> Roughly "30,000" companies acquired during periods of near-zero interest rates (2021-2022) are now "stuck" due to current higher rates and lower valuations. The IPO market, a traditional exit route, remains "still pretty poor."</li>
<li><strong>Cash Flow Issues:</strong> This lack of liquidity is causing "cash flow issues," leading to pension funds seeking to offload investments in secondary markets, typically "at a discount," indicating a "mispricing" of these assets.</li>
<li><strong>Critique:</strong> Private equity often "smacks of financial engineering" more than it genuinely "fixes" companies.</li>
</ul>
</ul>
</ul>
<h3>Key Sector Opportunities &amp; Emerging Trends</h3>
<ul>
<li><strong>Bullish on Financials:</strong> The firm is "quite bullish" on the financials sector, anticipating benefits from expected Fed easing and potential deregulation under a Trump administration.</li>
<ul>
<ul>
<li><strong>Regulatory Impact:</strong> Previous bank regulations inadvertently spurred the growth of unregulated "private credit markets."</li>
<li><strong>AI's Role:</strong> AI is expected to "really help banks just to reduce cost."</li>
<li><strong>Bank M&amp;A Needed:</strong> A wave of M&amp;A among regional banks is critical, as escalating regulatory and technology costs disproportionately burden smaller institutions, favoring large players like JP Morgan (whose deposit share grew from <strong>7% to 13%</strong> pre- to post-crisis).</li>
<li><strong>Cyber Threats:</strong> Cyber threats are an "increasingly significant issue," with expensive cyber insurance forcing some banks to self-insure, further benefiting larger entities.</li>
</ul>
</ul>
<li><strong>AI as a Fundamental Shift:</strong> AI is viewed as a "real thing," not a bubble, with "the sky's the limit" for its applications.</li>
<ul>
<ul>
<li><strong>Arms Race Dynamics:</strong> An "arms race" is underway among major public companies, driven by incentives to invest heavily, where CEOs face greater risk for *not* participating than for investing and potentially losing money.</li>
<li><strong>Skepticism on LLM Scaling:</strong> Some experts suggest that large language model (LLM) scaling may have "reached a dead end."</li>
</ul>
</ul>
<li><strong>Housing Market Insights:</strong> While affordability is a major issue—wages have not kept pace with the "level of prices" since <strong>2000</strong>—there are "signs of life" in housing statistics.</li>
<ul>
<ul>
<li><strong>Mortgage Rates:</strong> Mortgage rates have declined "about 100 basis points" (now around <strong>6% plus</strong>), though supply issues persist.</li>
</ul>
</ul>
<li><strong>Jason Trenard's Investment Focus:</strong></li>
<ul>
<ul>
<li><strong>Defense &amp; Space:</strong> Invests in defense stocks (aerospace and defense), particularly interested in the "space race idea" (e.g., anticipated SpaceX IPO).</li>
<li><strong>Hard Assets:</strong> Holds gold stocks (miners, GDXJ).</li>
</ul>
</ul>
<li><strong>Prediction Markets Convergence:</strong> A growing trend (e.g., PolyMarket) where individuals can bet on various outcomes (financial, political).</li>
<ul>
<ul>
<li><strong>Market Implications:</strong> These markets could become deep enough for hedge funds to use for risk offsetting.</li>
<li><strong>Regulation Urgency:</strong> These markets are "ripe for insider trading" due to a lack of regulation, necessitating oversight.</li>
</ul>
</ul>
</ul>
<h3>Notable Quotes</h3>
<blockquote>
"I am of the view that the man is always negotiating every like he wakes up in the morning. He's and he's to the extent to which he doesn't really care what other people think. Um and he is playing hard ball all the time. And so my inclination is that this is part of the negotiation process." - on President Trump's tariff threats
"I think people get confused what inflation is versus affordability and I think people forget in our business sometimes they forget that uh it's the level of prices that matter to the people." - on distinguishing inflation from affordability and the impact of wages not keeping pace since 2000
"The biggest change I I think and that's also part of the reason why you're seeing gold rally in my opinion because fiat currencies are are all fiat currencies are declining versus gold because no one has any fiscal discipline, right?" - on populism's impact on fiscal discipline and the rise of gold
"Just because you don't get a price every day doesn't mean there isn't actually inherent volatility, right? You just don't see it." - on the perceived low volatility of private equity investments
</blockquote>
                    </div>
                    <button class="toggle-btn" id="sum-btn-0" onclick="toggleSummary(0)">
                        Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>
                    </button>
                </div>
                
                <div class="transcript-section">
                    <button class="transcript-toggle" id="trans-btn-0" onclick="toggleTranscript(0)">
                        View transcript
                    </button>
                    <div class="transcript-content" id="transcript-0">
                        Stocks are down, gold is up, oil is up, crypto is down more than NASDAQ. Let's talk about the current economy.

Today we have Jason Trenard, who is the CEO and founder of Strategus. April last year, we had the whole tariff correction. President Trump is threatening tariffs with respect to Europe. It's like, are we really going to be doing this all over again? He is playing hardball all the time, and so my inclination is that this is part of the negotiation process. Bringing it to markets, we have more of a focus on industrials and materials. Those types of sectors, in our opinion, will do a lot better. I think you want something that can hedge yourself against inflation. The average person is behind what the level of prices have been since the year 2000. It's still an issue.

Hi, this is Steve Eisman, and welcome to another edition of the Real Eisman Playbook. Today we have a truly great guest, someone I've known for a very, very long time—a colleague, a peer, someone I respect deeply, and a friend, Jason Trenard. He is the CEO and founder of Strategus, a firm that many viewers should know very well. We've had several members of Strategus on over the last year or so. So Jason, welcome to the Real Eisman Playbook.

It's great to be here, and thanks for having so many of my colleagues on as well. It's terrific.

You run a great firm. Before we get started, because there's nothing really going on these days—actually, we're recording this one day after Martin Luther King's birthday—there's a lot of news about Greenland and tariffs; it's all back in the news. But before we get to that, let's talk about the elephant in the room. My viewers know that I've been dealing with cancer. There was an article in the New York Post about your dealing with cancer. Why don't you tell us a little bit about the ordeal that you've been going through?

It's kind of a shaggy dog story, and I'll try to make it as quick as possible. I'm 57. I may go to the doctor once a year, and then last year, about two weeks before I was supposed to start at the Treasury Department—I was going to be Assistant Secretary of the Treasury for Financial Markets—I was diagnosed with multiple myeloma.

Which is what?

It's a blood cancer. The good news is…

Were you feeling bad?

I was not feeling well for a couple of months. I was having headaches, medication really wouldn't work, and all the rest of it, where it had worked in the past. They admitted me almost right away into Memorial Sloan Kettering, and I was there for the better part of three weeks. The good news about multiple myeloma, a blood cancer, is that it's usually not fatal. It can be chronic, but it's not fatal, so you can live with it for a long time if you monitor it, do the right things, and get a little lucky. So that's good. The bad news is that with me, two things happened. One is that it damaged my kidneys to the point where I have to do dialysis three times a week now.

And you need a donor kidney?

I need a kidney. I would like one that's a direct match because that increases the chances of success after the operation.

So it was a double whammy, and then I had this severe neuropathy where I could barely walk. People with neuropathy—and I have a little bit of it as well—start to lose feeling in their fingertips and in their toes. If you get it really bad, like you got it, it's not easy to walk because you don't have any balance; you don't feel anything.

You don't have any balance, exactly. For the bottom part of your legs, you really don't do much. So anyway, I couldn't walk, I had no kidneys, and I had cancer. It was a pretty rough period of time, psychologically almost more than physically; physically it was terrible, but psychologically it was pretty bad too. The good news is it's all getting better, I think. The cancer is in deep remission. I don't need a walker anymore; I've graduated to a cane. I got a cane for a Christmas present. That's new, and we'll see about the kidney; I think that's going to work out.

I'm glad you're on the road to recovery. That's really great.

Yes.

Let's turn to the boring aspects of the market. What are your thoughts? In April last year, we had the whole tariff correction. As I said, we're recording this the day after Martin Luther King's birthday. President Trump is threatening tariffs with respect to Europe. He added this morning that he was going to maybe put 200% tariffs on French wine because President Macron would not join the Gaza Peace Accord, just to add insult to injury. The market today is down pretty good; it's a lot of pain. It's like, are we really going to be doing this all over again? Maybe we are. Give us your thoughts about this.

Steve, we were just talking about this in our morning meeting. We have about 30 people in there every morning, and that obviously dominated our conversation this morning. The debate was, should we start taking President Trump literally? There was this idea that you don't take him literally, but you take him seriously, or do you not take him seriously? In any event, I am of the view that the man is always negotiating. He wakes up in the morning, and to the extent that he doesn't really care what other people think, he is playing hardball all the time. So my inclination is that this is part of the negotiation process, and that we'll wind up with something, maybe more basis there, other things. I certainly don't think we want to. If we could own it, it would be great, but I certainly...

Why would we want to own it?

The biggest thing, and people aren't talking about it as much, I don't think, is rare earths in Greenland.

In Greenland, yes.

So I think that's it. It obviously has national security importance, but we could get that for free; we don't need to buy it. But I think the minerals and the rare earths there could be very meaningful, especially as we develop AI and as we grow the economy.

Let's turn to some things you've written lately. You wrote a nice piece about populism and the markets. Why don't you describe that piece?

Populism, we've talked about this for a long time. Populism has dominated the American political scene for the past 10 years, and I think it's because the average person has gotten tired of these social experiments from the left and the right that have not resulted in anything that has improved their lives.

So the WTO, trade with China, free trade with China, a country that's fixing its currency. And of course that was great for big businesses, but it wasn't for regular people. I'm for free trade, but again, if you're fixing your currency, it's not free trade. I think the average person would rather have a job than access to cheaper t-shirts or cheap tube socks. So there's that.

I think the Iraq war on the right—on the right, they tend to do their social experiments overseas. That was obviously a disaster in terms of blood and treasure. So I think that's been brewing for a while. I do think immigration and the environment were other things that you're seeing all over the world, really, with the north versus the south. Certainly in the Western Hemisphere, this uncontrolled immigration is, for lack of a better term, pissing people off. It's not only because of jobs, but because of the culture, all those things. You have to take that seriously. I don't think a lot of politicians have taken it that seriously.

I also think the environmental movement, particularly in Europe, got out of hand. Clearly, when you look at the auto manufacturers and all the rest of it, they're walking all that stuff back. It's just not realistic to do what everyone wants to do. You can't wave a magic wand and expect everybody to have electronic vehicles. I'm also a big fan of fossil fuels, in a way, because there are still a billion people on this planet that don't have access to any electricity or any power. So it's hard to ask them to wait for solar panels or whatever it is. I mean, I think we have to be just reasonable about it.

So let's bring it to markets. Populism definitely is a rising tide. What implications do you think that has for investing?

It will probably result in higher inflation because you're going to spend more money to keep people happy. And again, the right and left do that in different ways. The left does it by giving people money, and the right does it by letting rich people keep more of their money. So there's a difference there. That's the biggest change, I think, and that's also part of the reason why you're seeing gold rally, in my opinion, because all fiat currencies are declining versus gold because no one has any fiscal discipline. That's largely to keep, for lack of a better term, the great unwashed somewhat happy. I don't think it's working particularly well.

What do you think is not working?

I don't think it's particularly working well to just spend money we don't have. That's nothing new. The US can get away with it; it has the exorbitant privilege of having the reserve currency. Even though all the fiat currencies are declining versus gold, the dollar is down versus other currencies, but not ridiculously. Today is the one-year anniversary of the inauguration of President Trump, and we looked at the dollar index, which is down about 8%. Most of that happened right after liberation day, and it's been kind of flat since then, so it's not too bad.

So higher inflation, I think higher growth, higher nominal growth, and probably real growth as well. But we have more of a focus on industrials and materials. Those types of sectors, in our opinion, will do a lot better in the future. I think hard assets are also something, as we just talked about with gold, that a lot of wealthy people, sovereign wealth funds, fiduciaries, pensions, endowments, and foundations are going to want to have some sort of access to.

And when you say hard assets, what do you mean?

It would be gold, it would be farmland. It's debatable whether it would be crypto or Bitcoin.

We'll talk about that in a second.

I think you want something that can hedge yourself against inflation. I think that's true for both the average investor and the individual investor, and also true for institutions as well.

Let's talk about crypto for a second, because in theory crypto should be acting like gold. But I'll just point out that today, interest rates are up. Everybody's obviously worried, so it's risk-off. Stocks are down, gold is up, oil is up, crypto is down more than NASDAQ. NASDAQ is down, as of an hour or so ago, about 2%. Crypto is down anywhere from 3% to 6%. I always question, and I'm curious what you think, the investment thesis around crypto when on a day like this, in theory it should be up, but it's down. If it's down on a day like this, what's the thesis for owning it?

I don't know. Like you, I've been doing this a long time. You ask 10 people what crypto is still like, what's the thesis? They really can't say. The best thesis is that there'll be some sort of limited supply. That's not bad, but there are also issues with privacy and technology. It's not clear to me that it's something that people are going to want to own, or that they have enough confidence in to own, or that it's deep enough for global markets. So I think it's largely become a shadow of speculation; it's really become speculative.

It's another way to speculate.

Another way to speculate, which there's nothing wrong with that, but I'm not sure it's this idea that it holds some sort of intrinsic value.

You're skeptical.

I'm very skeptical, yes.

Let's talk about the current economy. Until today, tech stocks had sort of been correcting. The markets seemed to be broadening out. Industrials were up, housing stocks were up. I'm curious whether you think this is due to the &quot;one big beautiful bill&quot; starting to impact the economy. Where is Strategus on how the economy is doing these days?

Steve, I think for 2026, the economy is going to be pretty strong because of the &quot;one big beautiful bill.&quot; There's no question it's going to inject a lot of money into the system right away in terms of tax refunds and other stimulus for people. It's going to be probably $150 billion, and that'll get spent right away. Then you have all the supply-side provisions for an increase in capital spending, which is designed to have companies build plants.

You get to write off the entire cost of building a factory in the United States immediately.

Right, as opposed to amortizing it over five or 10 years. So it's a big deal. I think it's going to work to the extent that you're going to see companies take advantage of this and start to build plants. Whether it works fast enough to stave off inflation is another story. But I think for 2026, you've got this &quot;one big beautiful bill,&quot; you have the 250th anniversary of the country—the bicentennial—and then you also have the World Cup in the US. So you put all those things together, it's going to be a pretty good year, I think.

So you're pretty sanguine about the economy.

Sanguine about the economy. I think it would be hard to get a recession out of that. And certainly, expectations for earnings are that they'll be up, let's say, around 14% to 15% this year.

And GDP, what's GDP? We're at about three, for the whole year.

Yes, it's very good. And if you add 2.5% inflation on that, that's 5.5% nominal, not bad.

No, not too bad. Pretty good. The question again is, is it sustainable as we go into 2027? That will depend a lot on how successful some of these capital investments really are, whether they start to result in things that are positive or not. We'll see.

Where's your firm on the whole AI bubble, or not a bubble?

Steve, we've had to take a very practical, pragmatic approach to everything, because valuation, in a traditional sense, has not worked particularly well for a long period of time. The big five companies aren't actually that expensive, I guess. I don't think it's a bubble; I think this is the real thing. Now, whether the stocks are in a bubble, or whether these will be good investments, I'm not sure who the winners will be and all that, I'm not so sure. But I do think we're starting to try to use it in our firm, and we're generally late adopters of technology, but we're trying to be a little early on this one. I just think the sky's the limit there. How it'll be used, I think, we're figuring that out as we go along.

Interesting. I posted an interview yesterday with a guy named Gary Marcus, a former professor at NYU. He has this view that the whole LLM scaling has reached a dead end, and that he thinks it's going to slow—that's where the bubble is. We'll see; that's been his view.

He could very well be right. The issue is you've created this arms race with these big public companies where if you're the CEO of one of these companies, you get fired more quickly for not participating, for not investing, than investing and losing money. So I think there are incentives that way that probably lead you to overspending. He's probably right about that.

Let's turn to the big topic of concern, other than the other topic of concern, which is affordability. It's a big political issue. President Trump, I think tomorrow, is going to be talking about housing affordability. What's your view on housing stocks, and what's your view on the whole affordability concept and what it means for investing?

I'll start with that because I think people get confused about what inflation is versus affordability. I think people in our business sometimes forget that it's the level of prices that matters to people. It's not the month-on-month change or the year-on-year change; it's the level.

So in other words, if things slow from 2% to 1%, but you can't afford it anyway, what difference is it?

Precisely. And if your wages aren't going up as quickly as inflation, that's a problem. You saw that from 2000 to really now. The average person is still behind what the level of prices has been since the year 2000, which is to say that wages have not grown quickly enough compared to the year 2000.

Exactly, as far back as that, especially because I think in 2021 you had 9% inflation, and wages didn't go up nine.

That's for sure.

So you've had this—I don't want to say permanently high plateau—but you've had this quite high level, and wages for the average person haven't really participated. But we're getting there; we're chipping away at it. But it's still an issue.

As far as housing is concerned, our chief economist, Don Rissmiller, sees that there are actually some signs of life in most of the housing statistics that he looks at, which is very encouraging. If that were true, if this were the start of something big, I think it's a very big deal.

Just to point out, sorry to interrupt, today the 10-year yield is almost at 4.3%. That doesn't help.

No, it doesn't help, but mortgage rates are down. Mortgage rates are down about 100 basis points.

They're like 6% plus now.

Right. So that can help, but as everyone is pointing out, there are supply issues that contribute significantly to these problems. But in my opinion, it looks like from the data, housing is starting to percolate.

Interesting. And what did you make of President Trump's proposal about credit cards the other week?

This is the thing where, Steve, as you know, I'm a supporter of the President and was going to work for him. But I'm not a big fan, certainly not a big fan, of the populism in terms of setting prices for money. Setting the prices of money, I don't think, is a good idea. I don't think setting prices for anything is a good idea. I don't think it's a good idea to stop companies from buying back stock or paying their executives. I think the markets will kind of figure that out. But this is the populism we were talking about before. These are things that are quite popular with people, and with everyone, because you just see a 30% credit card rate roughly, and that makes people angry, whether you pay off your bill every month or not. So I don't like it.

In the past, that would have resulted in real pain. That alone, in my opinion, would have resulted in real pain for the stock market. If you remember 1962, President Kennedy had a showdown with US Steel.

Yes.

He essentially wanted them to roll back price increases, and that was seen as very anti-business. The market lost a third of its value and it stayed there for six to eight months before resuming its upward trajectory. So the world has changed a lot, obviously, but this is not, I don't think, a good habit to get into, getting in the way of free markets. It distorts the capital formation process.

Wouldn't you have to have Congress pass a law to put a cap on credit card rates, or not?

That's not clear to me.

It's not clear to me either, but Dan Clifton has told me that he's got to get it through Congress.

Okay, that's your politics guy.

That's our policy guy, who you've had on. He's great, the best, I think, on Wall Street. But it almost doesn't—I don't want to say it doesn't from a political point of view—it doesn't really matter. You're the person that's manning the ramparts and protecting people from evil pharmaceutical companies, evil banks, evil, and so on. It's ironic because he's, out of central casting, kind of the rich Wall Street Daddy Warbucks type of guy, and yet, this is who he is.

Let's switch gears for a second. One of the things I get from viewers all the time is, do I think the market is expensive or not? I'd be curious what you think, because that debate hasn't seemed to matter in a very, very long time. What are your thoughts on that, and why doesn't it matter?

The answer to the first question is I think the market is expensive by any historic metric. If you look at price-to-earnings, price-to-book, price-to-cash flow—anything where you have data—you're in the top couple of percent of all readings you've ever seen.

Okay.

So it's hard not to say the market's not expensive. There are things where you can whittle away at where it's acceptable. You could say AI would make it somewhat acceptable. That's a big, game-changing technology, so that's big. But the other reasons, I would say, are not so great reasons. One is that the Fed's balance sheet is still inflated; it's still large. There is a statistical break in the Fed's willingness to backstop problems, with the financial crisis, as you well know.

And it's become a habit.

Oh, I agree. I think financial—we call this financial repression, or quantitative easing—is a shiny new toy for a lot of central bankers, but I think it's done a lot more harm than good.

So let's talk about that for a second, because the quantitative easing that happened caused the stock market to go up. But let's talk about what you see as the negatives of it that have occurred.

Well, the negatives are, first, that it encourages financial engineering as opposed to real engineering. Your average company, knowing interest rates would stay low, would issue bonds and buy back stock, and your EPS goes up, and your stock goes up, and it's great; it's all good. Why build a plant when you can do that? That's one thing. Obviously, it hurts savers, hurts individuals to the extent that the rates are extraordinarily low. It distorts the capital formation process because you're funneling money into a lot of companies that may not eventually make it.

You've created private equity, for example. I've read there are now 31,000 unsold private equity companies that were basically bought during COVID and afterwards, and they can't be sold because when they financed the transaction, rates were basically zero, and now rates are significantly higher, and the valuations are much lower, and private equity doesn't want to sell. So they're stuck.

Yes, exactly.

That's a big negative, and I think a lot of people are going to—we could talk about private equity as well—those are some of the big problems with QE.

I'll give you another one. Everybody refinanced at 3%.

Right.

So now everybody's stuck owning their house; they can't sell.

Yes, right. So once you get in, in for a penny, in for a pound. Once you start this process, it's very hard to get out.

Without pain.

Without pain. And I would argue it puts the Fed in a position where it's not what the founders dreamed up. The founders didn't really think about a Federal Reserve, but the idea that you can essentially monetize the debt and allow politicians to spend whatever they want. That's another negative: the Fed says, &quot;We're the only game in town.&quot; Politicians are like, &quot;It doesn't matter, they'll just print more money, right? What's the problem? We're the reserve currency. What could possibly go wrong?&quot; Eventually something is going to go wrong, and I think the escape valve is probably going to be higher inflation, or significantly weaker currency, or both. So the Fed is actually almost stepping in as an active participant in the game when it really should just be a referee.

So basically, anytime anything goes wrong, the Fed says, &quot;Hey, we're here. We'll help out.&quot;

Well, I'll ask you. Silicon Valley Bank, I mean, that's...

I'd let it go down.

Yes. I never understood what the big deal was. It's not a big bank. But venture capitalists were screaming and yelling, &quot;The system's going to fall apart,&quot; and the Fed stepped in. It's like, okay, so the venture capitalists will lose some money. What's the big deal?

Right. So, going back to all these things, that's part of the reason why the market is expensive, that there's a backstop. They realize, &quot;What's the problem? If anything goes really haywire, the Fed will come in and save me.&quot;

How do institutional investors behave? You speak to institutional investors; what's the tone these days?

It's certainly not bearish. I would say it's cautiously optimistic. I've been around long enough; I've seen people really bulled up or really give you a hard time if you're somewhat cautious. This isn't one of those times. I think people are invested; they're fully invested, and they're probably quite long growth. By the same token, they understand that there are risks involved. I think where there's really offside, in my opinion, is not in the public markets, it's in the private markets. We'll have to talk about that in a second. But I think in public equities, people are invested. That's the main thing I can say: they don't like it, but they're fully invested.

Okay. So they're in, but they're not 100% happy about it.

No, I don't think so. The performance has been good, but it's enough.

So let's talk about private equity, private credit. What are you thinking these days? Being on a couple of investment committees, one of the things I realized is that a lot of institutions would rather have so-called low volatility than know the truth.

I want you to elaborate on that because I don't think all my viewers understand what I mean.

With public equity, you have the price every day, every millisecond of every day. Whereas with private equity, you mark it once a month, and it's marked to private equity; it's their own assumptions of what it's worth. So a lot of these institutions—as I said, pensions, endowments, foundations—they say, &quot;We don't want any volatility. We'll just buy private equity.&quot; But you have to ask yourself, does it make any sense that it has less risk if it's more highly leveraged?

Right. It doesn't make any sense. Just because you don't get a price every day doesn't mean there isn't actually inherent volatility; you just don't see it.

Right. It's like your house, in a way. You say, &quot;Well, what's the Sharpe ratio on your house?&quot; I don't know.

Oh, I would argue that the volatility of a private equity investment is much higher than my house.

Much higher.

Amen to that. Something that's leveraged—whatever it's leveraged to—that was leveraged when rates were zero, has got to have much higher volatility. The fact that you don't get a price every single day doesn't mean that it's not volatile.

No, amen to that. But the appeal is the opacity of the product.

Psychologically.

It's psychological. I also think it's, for lack of a better term, pragmatic. Let's say if you're a state pension plan out west.

Okay.

I've seen this where they go to the investment committee and they say, &quot;What can you give us this year? What do you think is a reasonable expectation for returns?&quot; And they say 5%.

The investment committee will say 5%.

And then the state will come back and say, &quot;No, it's seven. Figure out seven. We need seven, because if we don't get seven, we're going to have to cut back on benefits, or we're going to have to raise taxes, or we're going to have to do all these things because we have a balanced budget amendment that we don't want to do.&quot; So, voila, you get more investments in private equity, because it only seems to go up. The returns are inherently higher, the reported returns are inherently higher, and it solves a problem, going from 5% to 7%. I've seen that happen a lot of times.

Then there are also people that are very wealthy that are not particularly sophisticated, that don't realize that the fees are extraordinary. I think the last thing I saw is about 60% to 65% of all private equity transactions are to other private equity firms.

Yes.

So they're selling to each other; it's like a circle.

Exactly. So you have to wonder. I guess it's great as long as the music keeps playing. Well, the music isn't playing so well right now because, like I said, you have like 30,000 companies that were purchased in 2021 and 2022 when rates were very, very low. Rates are much higher now, these companies are highly leveraged, and the valuation of these companies is much lower. The IPO market, surprisingly, is still not that great, even though the market—I don't quite understand why—but it hasn't... there was a period last year where it got hot for a little while in the summer, and then it kind of died off. So the exit for private equity is still pretty poor. You keep hearing about pension funds getting increasingly upset and looking for ways to get out in these secondary offerings. All is not great in private equity these days.

No, it really creates a cash flow issue. I'm just thinking out loud here, but the other thing I've seen in terms of the secondary market for private equity is it's always at a discount.

Of course, it's never at par. So just to explain to viewers, a secondary market means if I have a pension fund and I'm unhappy that there haven't been a lot of companies that have been sold, I would like to sell, let's say, 20% of my investments in, I'll make it up, in Blackstone. So there's a secondary market. But if the companies that I own are priced at 100, and I want to get out, I'm not getting out at 100. I'm going to get out at some discount to 100—80, what? I don't know, but something.

Yes. I think that also gives you some indication that there's a mispricing, because people don't give stuff away for free. It doesn't really work that way. It's a good thing to the extent that it gets companies capital. It's a bad thing because it really smacks of financial engineering as opposed to... I'm not so sure how much value some of these private equity firms add to the companies that they're buying. That's the idea: you're supposed to really fix them, buy them, fix them up. It's not clear how much they really fix all the time.

They certainly leverage them. The leverage is easy. Fixing a company is not so easy, I don't think.

Let's switch gears for a second. Financials have done really well in the last year or so. What are the firm's thoughts on the deregulatory environment that we seem to be entering and what the implications of that are?

As a firm, we're quite bullish on financials. A big part of that is because the Fed is going to be—and our sector expectations are set on a year-ahead basis, not much further than that, because most of our clients have a one-year time horizon—but we think the Fed funds rate, the Fed is going to be easing, maybe not as much as people think, but they're going to be easing. And certainly, the Trump administration is nothing if not creative in finding ways to deregulate the financial industry.

I think just recently, when we talked about private credit, the more you regulate things, the more you're trying to diffuse a bomb that's already gone off, or things move in a different direction. So you create all these inhibitions for banks to lend, and so private equity makes sense. You create a private credit market which is completely unregulated. That's the issue. But I think your average bank is going to benefit from deregulation, lower costs. I also think—again, I'll ask you—but I think AI is one of those things that could really help banks just to reduce cost from a cost perspective.

I would agree with that. I also think, and I've said this before on my podcast, that we need a bank M&amp;A wave in this country, in the regionals.

Yes.

Because, I don't know if you know this, pre-crisis JP Morgan's deposit share was like 7%; today it's like 13%. And that's because of the cost of regulation, which if you're a big bank, you can bear a lot more easily. And the cost of technology is huge now, and you can bear that a lot more easily if you're big. So we need a lot more super regionals than we have. The only problem with the thesis, in terms of investing in it, is bank CEO egos get in the way. For example, First Horizon last year was viewed as a takeover candidate, and on the third-quarter conference call, the CEO gets on and says, &quot;I'm a buyer.&quot; The stock collapsed.

Right. Listen, it sounds like a dopey thing, but just from my knowledge of things, I would argue that some of these crypto threats or cyber threats through the internet are an increasingly significant issue for the banks, and it's something where you do have to be a larger bank to really handle those costs because the insurance costs are getting to the point now where some banks just have to self-insure against it.

Are you really hearing that it's that expensive?

Yes, it's that expensive. It's gone up dramatically in the last couple of years, and it's always out there.

So cyber insurance.

Cyber insurance.

A couple more thoughts. Let's talk about a change that has happened in the last several years, which is the power of retail and memes. That's different than it used to be. It used to be institutional investors dominated and controlled everything. Retail could go along for the ride but had no real influence. That's not true anymore. What are your thoughts on the implications of all that?

I think it could be partly because, first of all, there are fewer stocks—meaning meaningfully fewer publicly traded companies—in the US, so it becomes a little bit easier to manipulate them. But the other thing is you've gone to not having to have round lots; you can have online brokerages which allow people to invest very, very quickly. So all those things together...

And for free.

And for commission-free. That's the key: commission-free. Of course, nothing's free; there's always a cost somewhere, but when you're trading and it says free, it seems free. There might be some hidden costs, but you don't really know what they are, so for you, it's free.

Yes, that's right. It's free if you don't care what the costs are, or if you know that maybe you bought the stock a little more expensively than you otherwise would, but it looks free. This is another, I would say, unintended consequence of QE forever, is that you have a lot of money sloshing around. I have no problem with people making money with these online chats and all the rest of it, but it has changed the game quite a bit. It's getting a little bit, for the retail investor, akin to gambling, I think. I don't want to be judgmental about it; it is what it is.

Well, look, there have been stocks like Carvana, which got destroyed when the Fed was raising rates. It went down to like $4 and now it's $400. And that was a retail meme stock, and God bless the people who invested at $4 to $400. So they're constantly looking for a new type of stock like that, and whether it deserves it or not. Some of them have been on this company, OpenDoor, which I'm very skeptical about, but they have big influence.

When you and I started, this obviously didn't exist—the online chats and all the rest of it. Now you can get information out very, very quickly. You can manipulate stocks much more quickly if things go viral, like we've seen that. So that's kind of the downside of this. The idea of investing for the long term really gets pushed.

Lost in the wayside.

Yes.

All right, Jason, before we finish up, I'll give you the final word. Give us just some general thoughts about things. What are you thinking about these days?

Listen, again, this populism theme is the prism through which I'm seeing a lot of things these days. Sometimes you're right on certain investments for the wrong reason. Some things work out because you thought it was going to…

You had a thesis, but the stock went up anyway.

It went up. You thought it was going to go up because of X, and it went up because of Y. So this could be it. But I have to say, I do think a question you should always ask strategists and economists is what they're doing with their own money. It's a little harder these days because the banks have restrictions on what you can do with your own money. But even if you say, &quot;What would you do with your own money?&quot; for me, I have to say I own defense stocks. I own—it's kind of dystopian—and I own gold stocks.

You mean the miners?

The miners. GDXJ would be a good stand-in for that. Defense, meaning aerospace and defense. I'm very interested in this space race idea. I think that's something that's heating up big time. Last year, you saw some of the companies like Rocket Lab and Planet Labs, but you're going to have SpaceX IPO this year. So that, to me, is interesting.

The last thing I would just throw out there is I'm very interested in this convergence of the prediction markets and the financial markets.

Why don't you elaborate on that?

If people don't know, there are these markets out there, like Polymarket, where you can bet on just about anything. You could bet on the stock market during the next 30 minutes, or who will be the next Fed Chair, or whatever. What I'm finding is two things. One is that there are a lot of financial bets you can make that are not too different than buying a futures contract one way or the other. It wouldn't surprise me if hedge funds, at a certain point, if they get deep enough, would use them as a way to offset some of their risk or all the rest of it.

But they're growing like weeds, because certainly from an individual point of view, somebody who might not have an opinion on, let's say, the Giants this weekend, might have a very strong opinion about Greenland or whatever it is. So you're getting almost everybody into the pool that has an opinion, which is pretty much everybody. Whatever you're into—finance, fashion—there are bets that you can make. The exchanges are partnering up with these gambling sites and also these prediction markets. So you're seeing more and more of that. CME announced a deal with five states for FanDuel; it's now basically 50 states about three weeks later. Polymarket is actually a big holding of the Trump family, not insignificant, which is probably not a bad reason to own it. But that's partnering up with ICE. I think the exchanges are understanding that this is a new thing, and it's going to be something that a lot of people are going to get involved in.

I would also say, parenthetically, I hate to say this, but it probably should be regulated, because I can't think of anything that would be more ripe for insider trading than these markets. There'll be people that have knowledge, and it's not wrong; it's not illegal; it's not regulated. So you can kind of do whatever you want to do.

Any thoughts on the midterm election at this point, or is it too early?

I think it's always too early. Most people make up their minds in the last 90 days before an election, something like that. But if it were held today, I think the Republicans would probably get hurt across the board. Whether they would lose the Senate or not is quite debatable.

But certainly the House at this point.

Certainly the House at this point. Again, I have to say, I'm a rock-ribbed Republican; I hope the Republicans keep the majority in both houses, but you have to be realistic. There's also &quot;familiarity breeds contempt&quot; with the President, so there's going to be a little bit of that as well.

Okay, Jason, thank you. It's a real pleasure.

My pleasure, my pleasure. Thank you.
                    </div>
                </div>
                
            </article>
            

            <article class="video-card" id="video-1">
                <div class="video-header">
                    <h2 class="video-title">
                        <a href="https://www.youtube.com/watch?v=GZA1MAoywYA" target="_blank" rel="noopener">China's GalaxySpace To Launch More Satellites in 2026</a>
                    </h2>
                    <div class="video-meta">
                        <span class="channel-pill"><img class="channel-icon" src="https://yt3.ggpht.com/12DXqfZQBwvHFBp31Teww9briF_9d45RTmGp6fiYScdvI4LZ3xPEfmw54EXV4o6tQMuG1I2t4Q=s240-c-k-c0x00ffffff-no-rj" alt="" loading="lazy"><span class="channel-name">Bloomberg Technology</span><span class="channel-subs">(715.0K)</span></span>
                        <span class="meta-sep">·</span><span>11:27</span>
                        <span class="meta-sep">·</span><span>0.8K views</span>
                        <span class="meta-sep">·</span>
                        <span>2026-02-02</span>
                    </div>
                    
                </div>
                <div class="tldr">Galaxy Space, a rapidly expanding Chinese commercial satellite company, is leveraging strong government support and innovative, cost-effective technologies to deploy its mega-constellations and explore global markets.</div>
                <div class="summary-section">
                    <div class="summary-preview" id="preview-1">Galaxy Space, a rapidly expanding Chinese commercial satellite company, is leveraging strong government support and innovative, cost-effective technologies to deploy its mega-constellations and explore global markets. The company is focused on integrating its satellite...</div>
                    <div class="summary-full" id="full-1">
                        <h3>TL;DR</h3>
<p>Galaxy Space, a rapidly expanding Chinese commercial satellite company, is leveraging strong government support and innovative, cost-effective technologies to deploy its mega-constellations and explore global markets. The company is focused on integrating its satellite communication services with terrestrial 5G/6G networks to achieve ubiquitous connectivity, while also navigating the critical challenge of international spectrum coordination.</p>
<h3>Galaxy Space Overview &amp; Strategic Context</h3>
<ul>
<li><strong>Company Profile:</strong> Galaxy Space is a Chinese commercial company specializing in communication and remote sensing satellites, developing key technologies in this area.</li>
<ul>
<li>Has launched over 40 satellites to date and plans for further expansion.</li>
<li>Aims to produce innovative and efficient products for both domestic and global clients, securing more orders in the short and long term.</li>
</ul>
<li><strong>Favorable Policy Environment:</strong> The company benefits from a supportive environment for private and commercial space ventures in China.</li>
<ul>
<li>Chinese policy actively encourages the private sector to develop commercial space businesses.</li>
<li>Both central and provincial government levels are creating "good regulation structure" that companies like Galaxy Space are enjoying.</li>
</ul>
<li><strong>Role in China's Space Ambition:</strong> Galaxy Space is a key player in China's fast-growing space sector, contributing to multiple mega-constellation projects.</li>
</ul>
<h3>Technological Edge &amp; Cost Leadership</h3>
<ul>
<li><strong>Core Technology Focus:</strong> Since its establishment as a private company in 2018, Galaxy Space has prioritized developing key technologies.</li>
<ul>
<li>Achieved "very real technology breakthroughs" in satellite broadband communications and direct-to-cell technologies.</li>
<li>Also developed advanced massive solar panel systems for satellite energy.</li>
</ul>
<li><strong>Cost-Effective Manufacturing:</strong> The company operates an in-house "flexible, smart factory" for satellite production.</li>
<ul>
<li>This approach allows for cost reduction "without compromising any performances," meeting demand in a commercial and sustainable way.</li>
</ul>
<li><strong>Significant Cost Reduction (Antenna Example):</strong></li>
<ul>
<li><strong>Innovation:</strong> Successfully reduced the weight of a critical communication antenna from over 7 kilograms to less than half its original weight.</li>
<li><strong>Impact:</strong> This single design optimization reduces launch costs by over 50% due to the heavy charges associated with launching weight into space.</li>
<li>Further technical innovations enhance antenna performance (throughput) while further reducing costs, making satellite communication services "more affordable than the original players."</li>
</ul>
</ul>
<h3>Market Expansion &amp; Terrestrial Integration</h3>
<ul>
<li><strong>Global Market Strategy:</strong> Galaxy Space is actively exploring global markets, utilizing its "Constellation trial network" to validate technology and applications.</li>
<ul>
<li>Collaborates with local telecom and space players to identify real-world use cases and understand "pain points" for commercialization.</li>
<li>Recently secured a contract with a Thai telco, crucial for gaining experience in the Asian market.</li>
</ul>
<li><strong>Priority Target Markets:</strong> Based on economic growth, population density, and connectivity gaps, key regions of interest include:</li>
<ul>
<li>Southeast Asia, the Middle East, Africa, and Latin America.</li>
</ul>
<li><strong>Seamless Terrestrial-Space Integration (5G/6G):</strong> A critical focus is integrating satellite communication networks with terrestrial networks to create "ubiquitous" connectivity.</li>
<ul>
<li>This requires close collaboration with the telecom industry, especially operators.</li>
<li><strong>Key Challenge:</strong> Ensuring frequency allocation and spectrum sharing to prevent interference with terrestrial networks.</li>
<li><strong>Ultimate Goal:</strong> Provide smooth, uninterrupted services worldwide, with satellite communication becoming an integral part of future 5G and 6G infrastructure.</li>
</ul>
</ul>
<h3>Challenges &amp; Future Outlook</h3>
<ul>
<li><strong>Operational Headwinds:</strong></li>
<ul>
<li><strong>Launcher Sourcing:</strong> While manufacturing satellites in-house, the company sources launchers from various providers, considering different options.</li>
<li><strong>International Coordination:</strong> The "biggest challenge" identified is international coordination for spectrum allocation, required for each spacecraft.</li>
<ul>
<li>This necessitates more collaboration among different global players, including both sector-specific entities and government bodies.</li>
</ul>
</ul>
<li><strong>Lunar Exploration Ambitions:</strong> The company views lunar exploration as a "very big trend" globally, with significant progress being made by China.</li>
<ul>
<li>The speaker expresses personal excitement for further deep lunar exploration and anticipated milestones, such as orbiting the moon.</li>
</ul>
</ul>
<h3>Notable Quotes</h3>
<blockquote>
"Right now I think the policy sides are really having a good environment, creating a good environment for private companies, especially commercial companies like ourselves, because especially industries and industries and this kind of the tall policy structure and eventually in China, the Chinese policy is also you encourage the private sector to develop more to you both more, you know, commercial business of space." - on <strong>government policy support for private space companies</strong>
"When we started to market, such kind of antenna has a rates more than seven, seven kilos. So with our innovation and our optimization of design of such kind of antennas, we successfully. You reduced the weight of the antenna, half of the original weight of the original message. So which is a very big cost savings, because as we know, that when we launch the everything from ground to space, it needs are very, you know, heavy charges on the launching services. So once we reduce the antennas to not even to half of the original weight, we are actually reducing the calls to over 50% through this angle only." - on <strong>cost reduction through satellite component innovation</strong>
"But I think the biggest challenge right now in the industry is also we got into international coordination because for each spacecraft to launch into the space, you get a kind of a spectrum. You need a coordination among different players. That's where I think we are expecting for more collaborations between different players, either from the sector or from the government sector." - on <strong>the critical need for international spectrum coordination</strong>
"This integration actually needs more collaboration. The centralized industry is to work closely with the telecom industry, especially the telecom operators, because as I mentioned earlier, the frequency allocation, the spectrum is one of the important things in this industry. We have to make sure in the first step that the space communication network does not interfere with the terrestrial network." - on <strong>the challenges and importance of integrating space and terrestrial networks</strong>
</blockquote>
                    </div>
                    <button class="toggle-btn" id="sum-btn-1" onclick="toggleSummary(1)">
                        Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>
                    </button>
                </div>
                
                <div class="transcript-section">
                    <button class="transcript-toggle" id="trans-btn-1" onclick="toggleTranscript(1)">
                        View transcript
                    </button>
                    <div class="transcript-content" id="transcript-1">
                        My colleagues have just been talking through some of the milestones for China's space development. Galaxy Space is playing a significant role in megaconstellation projects. We are a Chinese commercial company focused on satellites, with key technologies in communication satellites and remote sensing. We deliver products and also launch satellites. So far, we have launched more than 40 satellites into space, and we are going to launch a small user space. China is growing very fast, with several mega constellations coming up. We are on this track, making efforts to ensure our products are innovative and efficient, so we can secure more orders in the short and long term. We also aim to create more innovative products for different clients, both domestically and globally. That covers what we are doing right now.

Regarding domestic support, the policy environment is very favorable for private and commercial companies like ours. Chinese policy encourages the private sector to develop more commercial space businesses. Our company is performing well. Both central and provincial government administrations are doing a great job creating a good regulatory structure for us. Companies like ours are enjoying this overall macro environment to develop and focus on our industries.

While we enjoy strong domestic support, we also consider potential headwinds, particularly concerning getting our satellites into space and launching them. Currently, we manufacture the satellites and source launchers to get them into space. We consider different options depending on various rocket providers and their offerings. The biggest challenge in the industry right now is international coordination. For each spacecraft launched, a spectrum is needed, which requires coordination among different players. We are expecting more collaborations between different players, both from the private and government sectors. We need more cooperation with operators and all global players.

While US and European leaders have historically led in early satellite deployment, China and our company have developed a strong edge. As a private company founded in 2018, we evaluated where we could excel and identified key technologies to focus on, such as satellite communication technologies. We have achieved significant breakthroughs in broadband communications, satellite direct-to-cell technologies, and massive solar panel systems, which power the satellites. We mature these technologies for deployment. A key strength of our company is our focus on cost-effectiveness. We built in-house facilities, including a flexible, smart factory, to produce satellites. This approach reduces costs without compromising performance, allowing us to meet demand and develop satellites commercially and sustainably in the long term.

To illustrate our cost savings with a ballpark figure, let's take the example of a critical satellite component: the communication antenna. When we entered the market, such antennas weighed more than seven kilograms. Through innovation and design optimization, we successfully reduced the antenna's weight to half of its original mass. This represents significant cost savings, as launching anything from the ground to space incurs heavy charges. By reducing the antenna's weight by over 50%, we achieved more than a 50% cost reduction just from this component. Furthermore, other technical innovations have further reduced costs while improving antenna performance and satellite throughput, making our satellite communication services more affordable than those traditionally offered by original players. This is a significant number in terms of cost savings.

The timing is crucial, not just for government backing and contracts for the private sector, but also for commercialization, as demonstrated by our recent contract with Thailand's telco. As a commercial company, we are actively exploring global markets. We have unique offerings, including a constellation trial network with satellites in space that allows us to validate technology and satellite internet applications. Our collaborations in Thailand and other emerging countries enable us to work with local telecom and space players. This collaboration helps us validate technology and apply our satellite internet solutions to local industries, identifying real-world use cases and market demands. Ultimately, commercialization requires finding tangible use cases for satellite services to complete the industry's commercial closed loop. We must identify real demands, genuine needs, and understand users' pain points, which is why we collaborate in different countries to address industry demands effectively.

While we are open to every global market, our priority markets, based on evaluations of economics, population, and connectivity gaps, are Southeast Asia, the Middle East, Africa, and Latin America. These regions have growing economies but still face connectivity challenges or have a high demand for satellite connectivity. These are the major markets we are targeting.

Ensuring the integration of satellite and terrestrial networks is a critical issue and a major potential for the satellite industry, especially as we move from 5G to 6G. The goal is to create a ubiquitous network of connectivity services worldwide. This requires seamless integration of space communication networks with terrestrial networks, demanding closer collaboration between the satellite and telecom industries, particularly with telecom operators. Frequency allocation and spectrum management are paramount; we must first ensure that space communication networks do not interfere with terrestrial networks. Through unilateral frequency sharing and the integration of space-based communication networks with terrestrial networks, everyone on the ground can enjoy smooth, uninterrupted services globally. This is our ultimate goal: for a 5G, or even 6G, satellite communication network to be an integral part of the global communication infrastructure.

Regarding lunar exploration, it is a significant trend, exciting industry players and ordinary people worldwide, not just in China but also in other developing countries. From China's perspective, our country and its industry players are making substantial progress. We have also contributed significantly to deep lunar exploration. As a fan of this industry, I look forward to achieving further milestones, such as orbiting the moon first.
                    </div>
                </div>
                
            </article>
            

            <article class="video-card" id="video-2">
                <div class="video-header">
                    <h2 class="video-title">
                        <a href="https://www.youtube.com/watch?v=jLVgGGz5bvk" target="_blank" rel="noopener">How to Think About Scale, Funding &amp; Competitive Positioning | David Solomon &amp; Ben Horowitz</a>
                    </h2>
                    <div class="video-meta">
                        <span class="channel-pill"><img class="channel-icon" src="https://yt3.ggpht.com/hkiO7UAtALrbqOcewo4CIrbd0j8XDeWttKkdtihfX1emeV4iUMwjIe1KKn4zd6wT2OOwANDnIA=s240-c-k-c0x00ffffff-no-rj" alt="" loading="lazy"><span class="channel-name">a16z</span><span class="channel-subs">(245.0K)</span></span>
                        <span class="meta-sep">·</span><span>35:35</span>
                        
                        <span class="meta-sep">·</span>
                        <span>2026-02-02</span>
                    </div>
                    
                </div>
                <div class="tldr">This discussion features insights from David Solomon (CEO of Goldman Sachs) and Ben Horowitz (Co-Founder of Andreessen Horowitz), covering the evolution of their respective firms, the current economic landscape, and the transformative impact of AI and policy.</div>
                <div class="summary-section">
                    <div class="summary-preview" id="preview-2">Here's a structural, hierarchical, and reader-friendly summary of the transcript, highlighting key nuances in quotes: This discussion features insights from David Solomon (CEO of Goldman Sachs) and Ben Horowitz (Co-Founder of Andreessen Horowitz), covering the evolution of their...</div>
                    <div class="summary-full" id="full-2">
                        <p>Here's a structural, hierarchical, and reader-friendly summary of the transcript, highlighting key nuances in quotes:</p>
<p>This discussion features insights from David Solomon (CEO of Goldman Sachs) and Ben Horowitz (Co-Founder of Andreessen Horowitz), covering the evolution of their respective firms, the current economic landscape, and the transformative impact of AI and policy.</p>
<p><strong>I. Goldman Sachs: Evolution, Strategy, and AI (David Solomon)</strong></p>
<ul>
<li><strong>Historical Evolution &amp; Culture:</strong></li>
<ul>
<ul>
<li>Initially a private partnership, Goldman Sachs was *“not a business built through a series of bank mergers”* but *“brick by brick by generations of entrepreneurial partners.”*</li>
<li>The firm *“stayed a partnership until the last moment when it absolutely couldn't be a partnership anymore”* due to the need for permanent capital, leading to its 1999 IPO.</li>
<li>A core challenge post-IPO has been to maintain its aspirational *“partnership culture”* while adopting the strategic direction necessary for a public company.</li>
<li>Goldman strives to be *“the most exceptional financial institution in the world,”* guided by four core values: client service, partnership, integrity, and excellence.</li>
</ul>
</ul>
</ul>
<ul>
<li><strong>Strategic Focus for the Future:</strong></li>
<ul>
<ul>
<li>As CEO, David Solomon prioritizes owning the firm's strategy, driving growth, and managing strategic risks to maintain relevance and competitiveness.</li>
<li><strong>Scale:</strong> A critical concern for institutional firms like Goldman Sachs and Morgan Stanley, which are the two smallest among the six most important U.S. financial institutions. Solomon emphasizes *“Scale matters a lot,”* stating that if JPMorgan's balance sheet is $4.5 trillion, Goldman's needs to be *“at least three and a half”* trillion (currently $1.9 trillion) to remain competitive, recognizing the difficulty of purely organic growth in mature businesses.</li>
<li><strong>Funding:</strong> Identifying wholesale funding as a major strategic risk (Goldman was *“the largest wholesale funder in the world 10 years ago. Wholesale fund not one of them.”*), the firm has successfully built a deposit platform to secure more stable funding, now accounting for 40% of its total funding.</li>
<li><strong>Technology:</strong> A continuous focus on leveraging technology to rebuild processes and operate differently while staying true to its core mission.</li>
</ul>
</ul>
</ul>
<ul>
<li><strong>Impact of AI on Goldman Sachs:</strong></li>
<ul>
<ul>
<li>AI is seen as an *“acceleration”* of technology's role in making productive people *“more productive, more powerful, have more impact”* through tools and applications.</li>
<li>A significant opportunity lies in *“really look[ing] at fundamental operating processes on a massive enterprise and completely reimagine[ing] them to automate them and make them more efficient.”* This strategic initiative (1GS 3.0) aims to create capacity for investment in growth areas.</li>
</ul>
</ul>
</ul>
<p><strong>II. Andreessen Horowitz: Founding, Evolution, and AI (Ben Horowitz)</strong></p>
<ul>
<li><strong>Founding &amp; Evolution as a VC Firm:</strong></li>
<ul>
<ul>
<li>A16Z was founded in 2009 during the financial crisis, a time when *“the best time to raise money is when nobody has money.”*</li>
<li><strong>Phase 1 (Achieving "Top Tier"):</strong> To compete with established VCs, A16Z designed a *“better product specifically for entrepreneurs,”* focusing on enabling founders to *“build his or her own company and run it as CEO,”* offering brand, power, and access.</li>
<li><strong>Phase 2 (Scaling):</strong> Inspired by Mark Andreessen’s *“software is eating the world”* thesis, the firm recognized the need to scale beyond the traditional small VC model (a good firm is *“like a basketball team, you know five maybe six players that's it”*) to address a growing market of valuable tech companies. This led to A16Z becoming *“the biggest”* VC firm, raising 18.3% of all US venture capital.</li>
<li><strong>Phase 3 (Industry Leadership):</strong> Guided by Andy Grove's principle that *“if you're the leader of an industry, then the growth of that industry depends on you,”* A16Z now focuses on broader initiatives like policy advocacy to ensure the US *“win[s] technologically”* and remains competitive globally.</li>
</ul>
</ul>
</ul>
<ul>
<li><strong>Policy Advocacy (Focused on Crypto &amp; AI):</strong></li>
<ul>
<ul>
<li><strong>Crypto:</strong> Advocated for crypto due to its importance as *“the most profound breakthrough in kind of financial technology”* and its potential to reshape society, arguing against the previous administration’s *“abuse of power”* and *“debanking”* tactics. They supported the Genius Act (Stable Coin Bill) and are pushing for the Clarity Act (Market Structure) to define token classifications and counter the *“everything's a security”* approach.</li>
<li><strong>AI:</strong> Ben warns against policies that could lead to *“regulatory capture”* or cause the US to *“lose the AI rights to China.”* Key policy goals include:</li>
<ul>
<ul>
<li>Not regulating the mathematical models themselves (*“don't regulate math”*), but rather *“the applications of that math.”*</li>
<li>Preventing a patchwork of *“50 different laws from 50 different states”* that would stifle innovation.</li>
<li>Allowing AI models to train on *“copywritten work”* (not reproduce it) to build more robust models, as China has no such restrictions.</li>
</ul>
</ul>
</ul>
</ul>
</ul>
<ul>
<li><strong>Impact of AI on Venture &amp; Tech:</strong></li>
<ul>
<ul>
<li>AI means *“leads aren't what they once were”* in tech, challenging the *“mythical man month”* concept. With AI, *“if you have proprietary data and you have enough GPUs, you can solve like almost any problem. It is magic.”*</li>
<li>This dynamic drives the need for companies to gain capital quickly to compete, predicting a surge in IPOs.</li>
<li>Ben expresses interest in *“AI gentic investing,”* but notes that models are based on available facts, while *“the biggest changes and the way you have to think about investing a portfolio comes from things that are completely new and unexpected.”*</li>
</ul>
</ul>
</ul>
<p><strong>III. Macro Economic &amp; Market Outlook (David Solomon &amp; Ben Horowitz)</strong></p>
<ul>
<li><strong>Current Macro Environment (David Solomon):</strong></li>
<ul>
<ul>
<li>Described as *“as sweet a spot that I've seen”* for financial and investable assets.</li>
<li>Characterized by a *“cocktail of stimulus”*: significant fiscal stimulus (including the "big beautiful bill"), monetary stimulus (rate cutting cycle), a *“capital investment super cycle”* (4 largest companies contributing 1% to GDP growth), and a deregulatory windback.</li>
<li>Despite this, *“average Americans definitely feel a lot of stress because everything's more expensive.”*</li>
<li>Market momentum is fueled by the President's quick adjustments to market conditions and the pull-forward of expectations due to *“productivity gains from AI investment.”*</li>
<li><strong>Key Risks:</strong> Geopolitics (moving towards a *“multi-polar world,”* higher risk) and the volatility and division created by social media.</li>
</ul>
</ul>
</ul>
<ul>
<li><strong>M&amp;A and IPO Expectations:</strong></li>
<ul>
<ul>
<li><strong>David Solomon:</strong> Predicts this year could be *“the biggest M&amp;A year in history”* and a *“bigger IPO year.”* This is driven by renewed confidence, shifting from four years where *“whatever the question was, the answer was no”* to now, where *“whatever the question is, the answer is maybe.”*</li>
<li><strong>Ben Horowitz:</strong> Agrees on the potential for many IPOs, some out of *“necessity”* for hyper-growth companies, and others driven by AI's impact on competitive leads, necessitating capital. He cautions on M&amp;A, noting it's *“not clear the FTC kind of position on these things yet,”* especially for big tech, potentially leading to more *“IP transactions”* than traditional M&amp;A.</li>
</ul>
</ul>
</ul>
                    </div>
                    <button class="toggle-btn" id="sum-btn-2" onclick="toggleSummary(2)">
                        Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>
                    </button>
                </div>
                
                <div class="transcript-section">
                    <button class="transcript-toggle" id="trans-btn-2" onclick="toggleTranscript(2)">
                        View transcript
                    </button>
                    <div class="transcript-content" id="transcript-2">
                        We were the largest wholesale funder in the world ten years ago. There are a lot of things you want to be the largest in the world; wholesale funding is not one of them.
&gt;&gt; We got a lot of criticism, like, &quot;Why are you raising money now? Are you stupid?&quot; It turns out that the best time to raise money is when nobody has money.
&gt;&gt; Last year, the four largest companies contributed 1% to GDP growth with their $400 billion in spending. M&amp;A, capital raising, and IPOs are driven by confidence. For the last four years, whatever the question was, the answer was no. Okay. Now, whatever the question is, the answer is &quot;maybe.&quot; David, you've been at Goldman now over 25 years. What are you focused on to position Goldman for the future?
&gt;&gt; If you're in our kind of businesses, if you're attached to financial assets, this is as sweet a spot as I've seen.
&gt;&gt; With AI, if you have proprietary data and you have enough GPUs, you can solve almost any problem. It is magic. I've had the distinct pleasure of working at least indirectly for both David Solomon and Ben Horwitz, and have a lot of affection for both Goldman Sachs and a16z. If you haven't read, I highly recommend reading the book *The Partnership*, which is written by a guy named Charles Ellis, which chronicles Goldman's nearly 160-year history. And I think the most remarkable thing about Goldman's history is the fact that it's not a business built through a series of bank mergers. Unlike many of its peers, it was really a business built brick by brick by generations of entrepreneurial partners raising their hand, going off, and building new businesses, whether it was expanding into Europe or starting the merchant banking business or the wealth management division. Many of these business units became global franchises. And I'd argue that Goldman was, and still is, one of the most entrepreneurial financial institutions in the world. And as I think about where we are in our own evolution at Andreessen Horowitz, I like to think that this is what Goldman Sachs must have felt like 50 or 75 years ago. A small group of entrepreneurial investors betting on a future...
&gt;&gt; ...weren't as rich as you guys that that...
&gt;&gt; Also, Goldman stopped speaking to Sachs forever.
&gt;&gt; Like, they got very mad at each other over – was it Sachs who supported Germany in World War I?
&gt;&gt; So, you actually remember your history. Wow. Yeah.
&gt;&gt; Well, yeah, a small partnership betting on the future with big hopes and ambitions. I'll leave it at that.
&gt;&gt; Well done, David.
&gt;&gt; Thank you. But perhaps, just pulling on that thread, David, you've been at Goldman now over 25 years. You joined the firm, I believe, in 1999, just after the firm's IPO: how has the firm evolved during your tenure? And maybe more importantly, what are you focused on to position Goldman for the future? Oh, before I begin, first of all, it's great to be here, great to be with everybody. Before I start on that, I'll just say one of the big lessons I've learned in my life is this: if you're joining a new firm that's a private partnership, don't spend six months negotiating so you carry over past the IPO date. Join before the IPO. It's a good lesson for all of you in private partnerships.
The firm's a remarkable place, and I really appreciate what you said about the firm and the entrepreneurial spirit of the firm. For a long time, the firm was a private partnership. The thing about private partnerships is that you have this mutual agency where people go off and do things. There's some structure that creates a collective each year or cycle where everything comes back, and then there's a re-evaluation of the partnership shares. You then go off again into the future to do more. And that served the firm incredibly well, and the firm stayed a partnership much longer than any other truly big Wall Street firm. But I'd like to say that the firm stayed a partnership until the last moment when it absolutely couldn't be a partnership anymore, because it needed the permanent capital to really make it a relevant business. If the firm hadn't gone public in 1999, it would have missed the global expansion of capital markets and probably would look more like, not to pick on anybody, but just to name one, more like Lazard today than Goldman Sachs. And so, the stewards of the firm at that point did an incredible job.
I think the challenge for us over the last 25 years, and I think the leadership team over the last eight years has really done an incredible job working together to address this, is that somehow, 25 years after an IPO, we still have this partnership culture. It's highly aspirational every two years to become a partner of Goldman Sachs; we have 450 people who are compensated in correlation to how the overall enterprise does. But the big thing that I'm really proud of, that we as a broad leadership team have done, is that we've started to recognize that we're not a small private partnership. You can't be a public company and not grow, and not have some form of top-down strategic direction. Yeah.
&gt;&gt; True.
&gt;&gt; But I think we've navigated well. I still think the principles and values that we, as a firm, kind of sit upon... We really strive to be the most exceptional financial institution in the world. We don't always get there, but we strive for that. We really sit on four core values: client service, partnership, integrity, and excellence. We try to live it, and I think the firm's in a really good place. But in some ways, it hasn't changed at all in 26 years. In other ways, it's changed massively.
&gt;&gt; Are there a few things you're most focused on as CEO looking forward over the next five or ten years?
&gt;&gt; Sure. One of the things I've learned—I was a banker and advised CEOs for a lot of my career—but actually owning the responsibility, that's one of my big takeaways from the last eight years: it's very different than giving advice. I think the most important thing a CEO has to do in a big enterprise like this is own the strategy and direction of the firm. And I'm focused on how we ensure we're executing toward growing the firm, because I know we have to do that to perform on a relative basis. But then I'm also thinking about, and worrying about, big-picture strategic risks that can make the firm less relevant, less successful, less important, and less competitive.
And for us, I think there are two things the firm is really focused on. First of all, one of the things that makes the United States an extraordinary place is that we have the most extraordinary capital markets, the most extraordinary financial system, and the most extraordinary financial institutions. I would argue that the six most important financial institutions in the US are all US financial institutions, and there is no global institution that can compete in terms of its relevance in the world with the six most important US institutions. When you look at those institutions, there are different kinds of institutions. There are retail banks, more traditional &quot;banky&quot; banks. That would include JPMorgan, Wells Fargo, Bank of America, Citibank. They all have global businesses, but they are truly banks in what they do. They have retail platforms, retail businesses. And then you've got two institutional firms. That doesn't mean they don't touch individuals in different ways, but Morgan Stanley and Goldman Sachs are both institutional firms. And Goldman Sachs is a little bit of an island of one in the context of the way we're positioned as an institutional firm. And Morgan Stanley is a little bit of an island of one in terms of the way they're positioned.
&gt;&gt; Scale matters a lot.
&gt;&gt; And I just went through all those firms. The two smallest of all those firms are Goldman Sachs and Morgan Stanley. And so, when there's turbulence in the world, you always want scale. Scale in these businesses, because they're so mature, gives you enormous leverage and latitude. And so, we continue to think a lot about scale, and we think out 5, 10, or 15 years: how are we going to maintain a level of scale that makes us competitive? Ten years ago, it would have been unfathomable that Goldman Sachs could have a $1.9 trillion balance sheet.
&gt;&gt; But at the moment, JPMorgan has a $4.5 trillion balance sheet.
&gt;&gt; When JPMorgan is at six, we're going to have to be at least three and a half. Or rather, at least three and a half. And so, we have to think about how we can continue to create that scale because these are very mature businesses, and it's hard to build that scale purely organically. So, that's one.
Second, funding. Funding these enterprises is one of the big strategic risks. These enterprises live on funding and liquidity, and we don't have a traditional deposit funding platform. We've got – and you participated in this – a very excellent digital deposit platform that now has over $200 billion in deposits. We also have about $500 billion in total deposits. Fifteen years ago, we had zero.
&gt;&gt; So, we fund about 40% of the firm's deposits, but deposits are a much more stable funding source than institutional wholesale funding.
&gt;&gt; Commercial paper.
&gt;&gt; Yeah. We were the largest wholesale funder in the world ten years ago. There are a lot of things you want to be the largest in the world; wholesale funding is not one of them. And so, strategically, that's another thing we worry about. So, those are big things for stepping back, getting away from the day-to-day execution, and thinking 10, 15, or 20 years out – which, by the way, I won't be here running the firm, but it's still my responsibility to steward and chart. In the short term, I'm much more focused on technology across the organization: how technology shifts the way we do things, how we're rebuilding processes, and operating differently while staying true to what we do.
&gt;&gt; Awesome. Well, we're here to help with that today, too.
&gt;&gt; Absolutely.
&gt;&gt; Ben, maybe transitioning to you. You and Mark started the firm at an auspicious time in the wake of the financial crisis in 2009.
&gt;&gt; 2009.
&gt;&gt; It turned out to be a really interesting moment because it was the beginning of mobile and the rise of the cloud.
&gt;&gt; Well, it's funny; we also got a lot of criticism in venture capital, like, &quot;Why are you raising money now? Are you stupid?&quot; But it turns out that the best time to raise money is when nobody has money. I mean, it's very obvious when you say it that way, but the nature of investing is that people always want to invest high and they always want to walk away when the market is low. It's just one of those things. So, we got very fortunate, I think. Yeah.
&gt;&gt; Maybe you can describe the evolution of the firm since you started, and again, what your ambitions are for the future as well.
&gt;&gt; Yeah. So, the original idea in venture capital – the fundamental thing you have to be – is what's known as top-tier, because if you're not top-tier, then the best entrepreneurs won't take your money. And so, there are times when, if the market is so blazing hot, you can be a less important venture capital firm and still dump into good deals and make money. But most times, if you're not top-tier, you're going to go out of business. So, you have to be that. The difficult thing about being top-tier is that historically, the way you became top-tier was reputationally. So, if you're a Sequoia, you had invested in Apple, Cisco, Yahoo, and Google. And so, it's really hard to make up that ground if you're starting in 2009. So, the idea we had originally to get to top-tier was to basically have a better product – a better product specifically for entrepreneurs. The venture capital product was great for LPs, but we thought it was mediocre for entrepreneurs. So, we designed the firm to really enable a founder to basically build his or her own company and run it as CEO. That wasn't really the idea back then; the idea was much more to replace the founder. There's a lot that went into it, and because we were founders, we knew what that was. So, we created a firm to give a founder a brand, power, access, and all these kinds of things. VCs said they did, but they didn't have to, because they were top-tier. It didn't matter. So, we did that, and that's how we got into a position to be a long-lasting firm.
The second phase was really based on something Mark wrote in 2011 called &quot;Software is Eating the World.&quot; And the idea with &quot;Software is Eating the World&quot; was this: if you looked at venture capital up to that point, there were studies that said in any given year, approximately 15 technology companies would reach $100 million in revenue, and those would be the companies worth money, and nothing else would be worth money. So, the whole venture capital &quot;sport&quot; was: how many of those 15 can you get into? Now, if software was going to eat the world, we thought maybe that 15 would become 150. And maybe one of the features of a venture capital firm is going to be that you're going to have to be able to scale it. Traditionally, I remember Dave Swenson, the great Dave Swenson, RIP, who ran the Yale endowment for years, saying to me, &quot;A good venture capital firm is like a basketball team – five, maybe six players, that's it.&quot; But you can't address a market where you have to be in 150 companies with six players. So, how do you organize? How do you scale? How do you design the firm so that you can get to the whole opportunity and yet still be really good at investing and not have more than five or six people talking about a deal?
And so, that was sort of phase two, and that's really when, I would say, we somewhat left the building in terms of what was going on in Silicon Valley, because nobody else was thinking that way. And so, last year – around 2025, I believe – about 18.3% of all venture capital raised in the US was raised by us. So, we're now from top-tier to the biggest. And going forward, what I think that looks like is... I get a lot of this thinking from my old mentor, Andy Grove. It was actually at the end of his life, but one of the things he said to me that I always remember – and for those of you who don't know him, he ran Intel and got it through that great memory crisis, changing the company; he was probably the greatest tech CEO we've seen – But he said something that is very obvious in a way, but also profound: &quot;If you're the leader of an industry, then the growth of that industry depends on you.&quot; You have to grow the market; nobody else is going to do it. That responsibility falls on you. And he really took that seriously at Intel. And so, when I think about what we are as a firm, a lot of it is incumbent on us. A lot of the work we've done on policy for crypto, and things we're doing internationally and on American dynamism, asks: How do we win? Not just Andreessen Horowitz, but how does the country win technologically? How do we continue to compete with China? How do we remain relevant in the next hundred years, like we were in the last hundred years? And that drives backward into how we think about how we have to develop some horizons.
&gt;&gt; Awesome. Maybe we'll transition just a little to markets. David, how would you describe the macro environment? What are you hearing from the CEOs that you work with and advise most closely?
&gt;&gt; Sure. First, Justin, Ben, and I were talking about this.
&gt;&gt; Good times.
&gt;&gt; If you're in businesses like ours – if you're attached to financial or investable assets – this is, I've been doing this for 40-some years, as sweet a spot as I've seen in terms of the macro picture. Now, that doesn't mean there aren't all sorts of difficult, complex things going on in the world, but I think we're at a moment. Let's just focus on the United States for a minute. We can go around the world and talk about anywhere you want, but let's just start here in the United States. The combination of the significant and continually increasing fiscal stimulus – and by the way, the big, beautiful bill that started in '26 just adds more to that. It's not that we weren't in a very stimulative place; we just added a whole bunch more. We have fiscal stimulus; we have monetary stimulus because we're in a rate cutting cycle. That doesn't mean I think we're going to see many more rate cuts, but we're probably going to see a couple more. We are in a capital investment supercycle, like something we've never seen. Last year, the four largest companies contributed 1% to GDP growth with their $400 billion in spending. We are in a deregulatory unwind cycle, moving from a massive regulatory surge during the last administration to a deregulatory wind-back that is very stimulative. All these things – it's just such a cocktail of stimulus – that it's very hard to slow the economy down. And while average Americans definitely feel a lot of stress because everything's more expensive, you could talk about inflation going from 9% to 3%, but the bottom line is everything is 25% to 30% more expensive. And that's how Americans feel it. There's pressure, but at the same time, there's enormous financial leverage that keeps the economy going and makes it a little more versatile. And so, if you own monetary assets or investable assets – if you're around growth and technology – this is a pretty prime environment.
I'll give you a hundred things that can set it off. Last April, if you were in Davos last January, people felt the same way. And then in April, we had a speed bump. But were all of you short the speed bump? And I think there are two things that have the market moving ahead. First, you've got a president who, if you look at the speed bump last April, marks to market to that market every single day. And second, the productivity gains from AI investment and putting it into the enterprise, and having the enterprise pick it up. The market is pulling forward a lot of what they expect to be delivered over the next one, two, three, or four years. And so, that's a pretty prime macro environment. Now, geopolitics are much tougher. We're moving back to a multipolar world, and the risk of a geopolitical problem that really slows down growth is higher. I'm not saying it's high, but it's much higher than it's been for the last 10, 20, or 30 years since the wall fell. Look, the world is fragile. Social media creates a lot of volatility and division. The way people absorb information and information moves makes the world faster-moving, but also more volatile. A lot can go wrong, but at the moment, from a base economic perspective, that cocktail of stimulus is pretty powerful.
&gt;&gt; Maybe a follow-up question for both of you: Do you expect to see a lot of M&amp;A or IPOs this year? How are you advising your CEOs?
&gt;&gt; We have a lot of them in the audience. It's a good banker response.
&gt;&gt; Just fact-based.
&gt;&gt; Okay, based on the very tough regulatory environment we had. M&amp;A, capital raising, and IPOs are driven by confidence. If you have a tough regulatory environment, that affects confidence. From an M&amp;A perspective on strategic M&amp;A, for the last four years, whatever the question was, the answer was no.
&gt;&gt; Right.
&gt;&gt; Okay, now whatever the question is, the answer is maybe. CEOs like to look forward; they like to do big things, they want to. So, there's a lot of activity, in fact. I just think again, this is an environment where you're going to see a significant year. I think this could be the biggest M&amp;A year – this is just me predicting – I think it'll be the biggest M&amp;A year in history this year. It's going to be a bigger IPO year, with a bunch of these big companies finally deciding they want to come through the pipe. But you'll have a view on that too. Being a public company is a horrible thing. I do not recommend it. It is challenging from a number of kinds of perspectives.
&gt;&gt; You just have to be okay with getting sued a lot, all the time.
&gt;&gt; It's funny. We had a company that just went public, and they were like, &quot;We might get sued.&quot; I was like, &quot;Of course you're going to get sued. You're public. This is America!&quot; What are you talking about? So, I agree. I agree a lot on the M&amp;A front, except with the exception that it's not clear what the FTC's position on these things is yet. And so far...
&gt;&gt; Yeah, especially on big tech. Even on small tech, they've been very aggressive.
&gt;&gt; So, I think M&amp;A will happen, but it may happen more in the form of IP transactions and that kind of thing, rather than as a traditional M&amp;A. I hope not, but that may be the case. And then, yeah, look, I think there's going to be a lot of IPOs coming out of our world. So, I think there's going to be some out of necessity, as companies are growing so fast. We have so many companies that went from zero to over $100 million in less than a year. Some went from zero to over a billion dollars in less than a year. Which we've never seen before. And then the corollary to that in AI is that leads aren't what they once were. For my whole life in technology, and for the whole history of software, there was this thing called &quot;The Mythical Man-Month.&quot; And the way &quot;The Mythical Man-Month&quot; puts it: nine women cannot have a baby in a month. So, if you're Google, you can't just put a thousand software engineers on a product and wipe out a startup, because you can only build that product with, say, seven or eight people. Once they figured it out, they've got that lead, and you're going to be behind for a long time. That's not true with AI. With AI, if you have data – particularly proprietary data – and you have enough GPUs, you can solve almost any problem. It is magic. But it means that you can throw money at the problem, and we've never had that in tech. And so, I think that's actually going to drive a lot of IPOs, because people are going to want to get out and have the capital to continue to compete, as it's really necessary. You don't just have a lead you can sit on. So, it's going to be a very exciting year, I think.
&gt;&gt; You were talking about the FTC earlier. I know you and Mark are spending a lot more time in DC than you ever have.
&gt;&gt; And Chris? Yeah.
&gt;&gt; What are some of the policy agendas you're most focused on, and why do you think this is more important now than it's ever been?
&gt;&gt; Well, the first one was crypto, because we thought then – and we continue to think – that crypto is an extremely important technology. It's not just the most profound breakthrough in financial technology that we've seen, but a real breakthrough in how society works. So, everything from how do property rights work on the internet, to what is the right architecture for things where creatives contribute most of the value, what's the right business architecture, what is stakeholder capitalism really... these are all things that get solved with crypto. So, we thought it was so important, and so important for the advance of society, and to not have us descend into communism and these kinds of things. It got completely banned by the last administration, but not through a legal or legislative process. Instead, it was through sheer will and, we'd say, abuse of governmental power, including techniques like debanking. Our company got Wells notices, which I've never seen before in a private company. So, it was just an attack from the government on an industry – a technology industry – in this country. And so, we were like, 'Well, we've got to get in and work on that.' The first thing was the GENIUS Act and the Stablecoin Bill, which passed and is now law, and we're very proud of that. The second one, which we think is the more important bill, is the CLARITY Act, also known as market structure, which establishes – and it's such a necessary thing for this technology, because you have these tokens that can represent a Pokémon card, that can represent a stock certificate, that can represent a dollar. There were no rules to say, 'Well, which one is this token?' And the approach of the Biden administration was that everything's a security, to the point where they sued artists for things like, 'Oh, I painted a picture and I made an NFT. Oh, you sold a security!' That's crazy. So, this one we're trying to get passed right now, and we've had some drama around it, which I'm not going to comment on, but that's a thing.
The second really important one is AI. I think with new technologies like the automobile or electricity, people tend to freak out about them because they do have a big impact; they are going to change the world. With AI, in particular, some of the calls are coming from within the house, where people are really trying to scare the population, sometimes to achieve regulatory capture and other things. But if you ban the technology – which some people are calling for – or infringe people's ability to do mathematics, then I think we're definitely going to lose the AI race to China, which has massive, 100-year implications. So, the key things we're trying to protect are: first, the model is the model. It is a mathematical model. It predicts things. It's not a sentient being. Maybe we'll figure out how to do that, but we don't know how to do that yet. So, it's not sentient. It's just a model. So, we're trying to say, 'Don't regulate math.' Regulate the applications of that math. So, if somebody uses AI to break into a bank, steal your money, or make a robot that shoots somebody, then that's illegal. But the technology itself shouldn't be illegal. The most pressing issue right now is that every state wants to have its own set of AI laws, which will basically make it impossible for new companies to innovate because you can't comply with 50 different laws from 50 different states. So, we're trying to get that done. Shortly following that, there's an issue of how copyrights are treated: can you build a statistical model over copyrighted work – not reproduce the copyrighted work, but just build a model about it – so that the software becomes smarter? We think that's very important because China absolutely doesn't respect copyrights. They don't even respect just copying it, let alone building a statistical model. We're going to have a weaker AI if we can't train on all the data, if we can't train on the complete data. So, those are the main things that we're trying to push forward.
&gt;&gt; Awesome. One of the things that was very evident to me during my time at Goldman was how client-centric the firm was, and I know 1GS was a big focus of yours. I'm curious how AI is changing the way you both work internally, and also how you're delivering better for clients.
&gt;&gt; Sure. Well, the firm's business is serving our clients. Technology has, for decades, been making productive people more productive. Goldman Sachs is a professional services firm filled with very productive people, and technology has been changing the way they work, evolving it, making them more consequential, and allowing them to expand the scope and footprint of what they impact. This technology is another acceleration of that, for sure. In the simplest form – and this is a broad oversimplification, so please take it as such – there are two things we're focused on. First, we've got lots of smart people. These are tools and applications. We're trying to get them into their hands and give them access to them – access to models and access to applications. So that they can experiment with them, play with them, and figure out how, on a day-to-day basis, as they're executing for clients and doing the things they're doing, they can be more productive, more powerful, and have more impact. We're good at this. We've done this before. Our people are good at it. It takes time, but we know how to do this, and we're doing it. It's really constrained by how we get the best tools, models, and applications – and by the way, get them regulatory-cleared – because we have to deal with regulatory constraints in everything we touch and do. That's a huge barrier for us. We're just not a company that can say, 'Oh, this is great! Let's try it!' We have to have a huge process before we can try anything. But we know how to do that; we're doing that, and it is expanding the productivity of our people, and you see real-time uptake on that that's really accelerating.
The more interesting thing to me as the CEO is that this technology allows us to really look at fundamental operating processes on a massive enterprise and completely reimagine them: to automate them and make them more efficient. Not simply for the benefit of doing them with fewer people or at less cost, but for the benefit of taking some of that savings and giving us more capacity to invest in growth areas of the business where we're constrained. And so, we don't have the ability to just spend as much money as we want and lose as much money as we want. We actually have to be held accountable every year for how much money we spend, how much money we make, and what kind of a return we generate.
&gt;&gt; Thanks. Generally, that doesn't last forever.
&gt;&gt; No, they don't last forever. But interestingly, there are companies that have proven they can last for 10-15 years where the accountability for the way you're deploying your capital is put off for a long period of time. We have to look at it every year. So, I would say in the last few years, we've been constrained. Simply put, last year we spent $6 billion on technology. I would have loved to spend eight. But if I had spent eight, our returns would have been hundreds of basis points lower. And we couldn't do that. Sure. Now, if we can actually find $2 billion of efficiency by reimagining processes, then I can spend eight and wind up with the same returns. So, we laid out a program – we actually called it 1GS 3.0 – where we picked six specific processes in the firm, and we said we are going to do the work to completely reimagine them. We have not put out publicly how that changes workforce, how much capacity that creates, but it's super significant. And it's not that there are only six; these are just the first six. So, this is one of the reasons why the market's running forward. I think this opportunity is huge, but this is hard. This is hard because you're asking people to, in a way, take away their empire and do their empire differently. It's got to be driven top-down, and it's hard, but we're going to make a lot of progress. So, those are two simplifications, but they're two big things I like to sum up.
&gt;&gt; Anything, Ben, you'd add to that? Where do you see the proliferation of this technology in the enterprise, and what are you most optimistic for in the next, say, five to ten years?
&gt;&gt; Well, I think for the reasons David cited, we're at the very beginning in the enterprise. Changing people and processes and so forth in a big existing company is, no matter what the technology is, complicated. In our firm, as you know, we're taking a very aggressive approach to first automating all the things people do and don't like to do, or, it's not the funnest part of the job. We've also gotten all of our hard data into a Databricks data lake, so we can basically ask any question about the firm or the portfolio. Customer support for it works fantastically. AI-centric investing is going to be very interesting because models work on the facts that are available. One of the things about investing is that sometimes the biggest changes and the way you have to think about investing a portfolio come from things that are completely new and unexpected. It can't be incorporated into a model; it can't be something from the past. Yeah. So, the bottom line is once it happens, it can be quickly incorporated into models, and models can learn very quickly. But still, you start from a place. I'm really interested to see how it works. Look, one of the things you've got to wonder is why there are a handful of people who have so outperformed as investors over a long period of time, but you also encounter people who underperform. And so, if the models are based on the information that the underperforming people all have, it's going to be interesting to see whether something different comes out of it.
&gt;&gt; Awesome. I think we're running out of time, but maybe one last bonus question: Favorite DJ? No self-nominations.
&gt;&gt; Favorite DJ today?
&gt;&gt; Yeah, or it could be in the past.
&gt;&gt; John Summit.
&gt;&gt; Okay.
&gt;&gt; John Summit is doing really cool things as a DJ. He's an incredibly interesting young guy that's got a lot of energy, and he's evolving the context of how big clubhouse DJs do what they do. I think he's doing a great job.
&gt;&gt; Ben, I'm going to stay in my lane, which is the past and hip-hop DJs. I'm going to say DJ Jazzy Jeff. He's very underrated because his partner, the Fresh Prince, became Will Smith. But DJ Jazzy Jeff is a great, all-time DJ. Yeah. Awesome. Thank you guys so much for doing this.
&gt;&gt; Thank you, David.
&gt;&gt; Awesome.
                    </div>
                </div>
                
            </article>
            

            <article class="video-card" id="video-3">
                <div class="video-header">
                    <h2 class="video-title">
                        <a href="https://www.youtube.com/watch?v=zbiEYMapsvw" target="_blank" rel="noopener">NVIDIA &amp; Eli Lilly: The AI Revolution in Drug Discovery | Jensen Huang &amp; David Ricks</a>
                    </h2>
                    <div class="video-meta">
                        <span class="channel-pill"><img class="channel-icon" src="https://yt3.ggpht.com/btm1_PK-7VRUr9GY2D0UV_2XfbUZPBjghyptjSO1crsfN86HyTYDWPmUbq7JxC3H0Lxe_s067nA=s240-c-k-c0x00ffffff-no-rj" alt="" loading="lazy"><span class="channel-name">NVIDIA</span><span class="channel-subs">(2.1M)</span></span>
                        <span class="meta-sep">·</span><span>58:44</span>
                        
                        <span class="meta-sep">·</span>
                        <span>2026-02-02</span>
                    </div>
                    
                </div>
                <div class="tldr">&gt; &quot;In the last 10 years, we've accelerated AI about a million times.</div>
                <div class="summary-section">
                    <div class="summary-preview" id="preview-3">TL;DR: NVIDIA and Eli Lilly are partnering to revolutionize drug discovery by building the world's largest dedicated on-prem biology supercomputer and a co-innovation lab, applying advanced AI to simulate human biology and accelerate the development of new medicines.   ...</div>
                    <div class="summary-full" id="full-3">
                        <h3>Executive Briefing: NVIDIA &amp; Eli Lilly: The AI Revolution in Drug Discovery</h3>
<p><strong>TL;DR:</strong> NVIDIA and Eli Lilly are partnering to revolutionize drug discovery by building the world's largest dedicated on-prem biology supercomputer and a co-innovation lab, applying advanced AI to simulate human biology and accelerate the development of new medicines.</p>
<h3>## The NVIDIA AI Advantage &amp; Accelerated Computing</h3>
<ul>
<li><strong>Accelerated Computing Evolution:</strong></li>
<ul>
<ul>
<li>NVIDIA has pioneered accelerated computing for 33 years, achieving <strong>1 millionx AI acceleration in 10 years</strong>, significantly outpacing Moore's Law (100x over 10 years).</li>
<li>This acceleration, achieved by co-designing the entire computing stack, aims to tackle humanity's most impactful challenges.</li>
</ul>
</ul>
<li><strong>Transformative AI Breakthroughs:</strong></li>
<ul>
<ul>
<li><strong>Computer Graphics:</strong> Ray tracing, once a decades-long problem, is now real-time and photorealistic in games, augmented by AI.</li>
<li><strong>Self-Driving Cars:</strong> Approaching a "ChatGPT moment," with robo-taxi capabilities becoming standard in new cars within a decade, driven by multimodality AI and reasoning.</li>
<li><strong>Generative AI &amp; LLMs:</strong> Recent breakthroughs in multimodality AI, reasoning, and agentic capabilities have transformed AI into an "incredibly useful" tool, applicable across diverse industries, including life sciences.</li>
</ul>
</ul>
<li><strong>NVIDIA's Life Sciences Platforms:</strong></li>
<ul>
<ul>
<li><strong>Key Libraries:</strong> NVIDIA offers platforms like <strong>Parabricks</strong> for gene sequencing (achieving a Guinness World Record), <strong>MONAI</strong> (an open-source platform for medical imaging with 6 million downloads), and <strong>BioNeMo</strong> for understanding geometric structures like molecules and proteins.</li>
<li><strong>Dominant Role:</strong> The vast majority of the world's structure prediction models are built on NVIDIA platforms today.</li>
<li><strong>Pre-trained Models:</strong> BioNeMo includes pre-trained models and data for protein design (<strong>Laortina</strong>), molecular synthesis (<strong>Resin</strong>), toxicity prediction (<strong>Kermit</strong>), DNA foundation models (<strong>Evo 2</strong>), and RNA design (<strong>Codon FM</strong>).</li>
<li><strong>Future Vision:</strong> Developing foundation models for proteins, with foundation models for cells "just around the corner."</li>
</ul>
</ul>
</ul>
<h3>## Eli Lilly's Innovation Strategy &amp; GLP-1 Success</h3>
<ul>
<li><strong>Resilience &amp; Accelerated R&amp;D:</strong></li>
<ul>
<ul>
<li>Eli Lilly, a 150-year-old company, has a history of navigating challenging industry cycles and patent cliffs by being "relentless on invention," uniquely surviving without mergers.</li>
<li><strong>Streamlined Processes:</strong> Lilly systematically optimized its R&amp;D, making it approximately <strong>40% faster</strong> than other large pharmaceutical companies, enabling invention within existing patent cycles.</li>
</ul>
</ul>
<li><strong>GLP-1 Market Leadership:</strong></li>
<ul>
<ul>
<li><strong>Pioneering Role:</strong> Lilly launched the world's first GLP-1 treatment in 2006.</li>
<li><strong>Strategic Execution:</strong> Through sustained innovation, including the development of Tirzepatide (a dual GLP-1/GIP medicine like Zepbound), Lilly became the market leader in GLP-1 treatments last year, with a triple-acting variant anticipated in 2027.</li>
</ul>
</ul>
<li><strong>Continuous Innovation:</strong> CEO David Ricks emphasizes the ongoing need to create conditions for new "success cycles" to ensure sustained growth and impact beyond current blockbuster drugs.</li>
</ul>
<h3>## A Transformative Partnership: NVIDIA &amp; Eli Lilly Co-Innovate</h3>
<ul>
<li><strong>Shared Vision for Infrastructure:</strong> Both Jensen Huang and David Ricks highlight the critical importance of building advanced computing infrastructure to attract top scientific talent and foster groundbreaking discoveries in AI and biology.</li>
<li><strong>Key Partnership Pillars:</strong></li>
<ul>
<ul>
<li><strong>Biology Supercomputer:</strong> The world's largest dedicated <strong>on-prem biology supercomputer</strong> is being built in Indianapolis, expected to be operational this week.</li>
<li><strong>Bay Area Co-Innovation Lab:</strong> A joint Lilly-NVIDIA AI lab will be established in the Silicon Valley area, bringing together leading computer scientists and drug discovery experts.</li>
</ul>
</ul>
<li><strong>AI-Driven Discovery Mechanisms:</strong></li>
<ul>
<ul>
<li><strong>Foundation Models:</strong> The lab will focus on developing new foundation models for proteins and cells.</li>
<li><strong>Closed-Loop Scientific Flywheel:</strong> AI will drive protein/chemical synthesis, which will then be validated in robotic wet labs to collect ground truth data. This data will continuously feed back into the models, creating a "scientific flywheel on steroids" to accelerate discovery.</li>
</ul>
</ul>
<li><strong>"Digital Twin" for Biology:</strong></li>
<ul>
<ul>
<li>Jensen Huang envisions applying the "computer-aided design" paradigm, which allows 15,000 engineers to design complex chips that work perfectly on the first try, to human biology.</li>
<li>This aims to transform drug discovery from an "empirical" process (like "wandering around the forest looking for truffles") into a precise engineering problem, performing much of the work "in silico."</li>
</ul>
</ul>
</ul>
<h3>## Beyond Obesity: AI's Role in Future Healthcare Frontiers</h3>
<ul>
<li><strong>Broadening GLP-1 Impact:</strong></li>
<ul>
<ul>
<li><strong>Chronic Disease Lynchpin:</strong> Obesity is a key driver for over 200 chronic diseases; GLP-1s provide a synthetic "off switch" for hunger, addressing modern caloric abundance.</li>
<li><strong>Expanded Benefits:</strong> Zepbound users experience an average 23% body weight loss and a 93% reduction in pre-diabetes conversion. Emerging research shows non-obvious benefits, including reduced chronic inflammation (e.g., improved psoriatic arthritis) and potential in brain health (addiction, gambling, alcohol, smoking cessation).</li>
<li><strong>Future Delivery &amp; Reach:</strong> An oral GLP-1 form is set to launch this spring, significantly enhancing convenience and global scalability, especially for regions with high diabetes prevalence like Southeast Asia.</li>
<li><strong>Historical Parallel:</strong> David Ricks likens the potential impact of GLP-1s to that of antibiotics, which drove a 60-year wave of medical breakthroughs by conquering acute infections.</li>
</ul>
</ul>
<li><strong>Focus on Healthy Longevity:</strong> Eli Lilly's approach to longevity is to extend healthy human lifespan by eradicating disease (e.g., through GLP-1s addressing chronic ailments) rather than solely focusing on extending maximum biological shelf-life.</li>
<li><strong>Next Frontier: Brain Health:</strong> Significant efforts are directed at tackling dementia and other diseases of the aging brain, leveraging AI to simulate brain tissue, understand complex interactions (e.g., inflammation, protein misfolding), and discover new therapeutic targets.</li>
</ul>
<h3>## Accelerating Drug Discovery Through AI &amp; Collaboration</h3>
<ul>
<li><strong>AI Lab Research Directives:</strong></li>
<ul>
<ul>
<li><strong>Drug Engineering/Optimization:</strong> A highly tractable problem for the joint lab, focusing on optimizing new modalities (e.g., RNA, gene therapies) and refining drug designs for known targets.</li>
<li><strong>Target Discovery:</strong> A more challenging endeavor requiring robotic wet labs to run 24/7, generating massive experimental data to fully profile targets and their structural complexities, closing the loop with engineered drug designs.</li>
</ul>
</ul>
<li><strong>Synthetic Data Flywheel:</strong> The ultimate vision involves creating a "synthetic data flywheel" where AI models are trained and tested against sophisticated "world models" (representing the lab itself), reducing the need for constant physical experimentation while remaining grounded by real-world data.</li>
<li><strong>Collaborative Ecosystem:</strong></li>
<ul>
<ul>
<li><strong>Tune Labs:</strong> Lilly's visionary platform, built on NVIDIA's federated learning (NVFlare), enables startups and third parties to collaborate on drug discovery, contributing data and benefiting from improved models without co-mingling sensitive intellectual property.</li>
<li><strong>Broader AI in Healthcare:</strong> AI is rapidly being adopted in healthcare services (e.g., agentic AI, Lilly Direct's $4B/year pharmacy platform) to enhance efficiency and foster innovation, despite existing industry frictions.</li>
</ul>
</ul>
<li><strong>Lilly's Tech Legacy:</strong> David Ricks highlights Lilly's long history of leveraging cutting-edge technology, including developing the first approved biotech product (Humulin with Genentech), acquiring the first pharmaceutical supercomputer (a Cray "Big Red"), and designing the first computer-designed medicine (Humalog). This partnership is a natural evolution of that legacy.</li>
</ul>
<h3>Notable Quotes</h3>
<blockquote>
"In the last 10 years, we've accelerated AI about a million times. A million times versus a hundred times. A million times compounded over 20 years gives us an opportunity to maybe address some of the most incredible, most impactful challenges of humanity."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>Jensen Huang, CEO, NVIDIA</strong>
"We systematically took apart the R&amp;D process literally like every step... and we squished the time. And so still today probably Lily is about 40% faster than the next scaled pharma company on average across all therapeutic areas."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>David Ricks, CEO, Eli Lilly</strong>
"Finally, the computer you know a million times a million times a quadrillion times of computing power later. I think finally we might be able to represent one of the hardest problems in the world which is the human biology. And I'm really hoping that your industry moves from drug discovery, which is kind of like wandering around the forest looking for truffles, to being an engineering problem."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>Jensen Huang, CEO, NVIDIA</strong>
"If we can make that an engineering problem versus this sort of discovery arteasonal drug making problem, think of the impact on human life."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>David Ricks, CEO, Eli Lilly</strong>
</blockquote>
                    </div>
                    <button class="toggle-btn" id="sum-btn-3" onclick="toggleSummary(3)">
                        Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>
                    </button>
                </div>
                
                <div class="transcript-section">
                    <button class="transcript-toggle" id="trans-btn-3" onclick="toggleTranscript(3)">
                        View transcript
                    </button>
                    <div class="transcript-content" id="transcript-3">
                        Hello. It's great to see all of you. Once a year I get the benefit of thanking all of you for the incredible work that you do. As you know, we pioneered a new way of doing computing called accelerated computing. And we've been working on this for now 33 years. The big idea is that if you could co-design – meaning if you understood the problems you're trying to compute for, and you developed the entire stack, including the algorithms, the computers, and the processors within it – if you co-designed, solving the problem from top down, from bottom up, and inside out, you could accelerate these applications, which are incredibly computing intensive, by a level that Moore's Law would only dream of. Moore's Law runs at about 10 times every 5 years, 100 times every 10 years. In the last 10 years, we've accelerated AI about a million times. A million times versus a hundred times. A million times compounded over 20 years gives us an opportunity to address some of the most incredible, most impactful challenges of humanity. That's you. And so we've been thinking about accelerated computing and this co-design idea for a very long time.

After some 30 years or so, each of these different fields of computing domains became within reach. One of the first ones was computer graphics. Somebody told me about 10 years ago that it would take 30 years for us to solve this incredibly hard problem called ray tracing for computer graphics. Literally following every photon of light as it bounces around the room, eventually reaching your eyes. Using ray tracing, you could solve for really interesting computer graphics problems and create photorealistic images like this. That was 10 years ago that it would take 30 years. It was the computer graphics problem that was always the future. And literally today, we ray trace every single pixel in a computer graphics program in our video games. Not only do we ray trace it incredibly beautifully, we do it at several hundred frames a second, at as large a resolution as you like. We've taught an AI how to, we've taught our computer how to simulate with first principle simulations for very few pixels. And then we use AI to predict the rest of it. We teach an AI what an image should look like, and it generates the image for us. It's temporally consistent. It's spatially consistent. It's incredibly beautiful. It looks even better than we compute.

Each one of these different domains is becoming within reach. About 10 years ago, we started talking about self-driving cars. Today, I think we are at the ChatGPT moment of self-driving cars. There's no question in my mind that within the next 10 years, almost every car that gets manufactured will have either robo-taxi capability, or if you like to drive yourself, you still can, but it has the ability to be a robo-taxi. That future is just around the corner. Each one of these domains is within reach.

Now, of course, we now have the ChatGPT moment. The last year we've seen incredible progress in generative AI in large language models. These ideas made it possible for us to take an AI that we thought was magical but hallucinated a great deal. It went from essentially cute and very interesting to something that is incredibly useful. This last year, and over the last couple of years, we saw breakthroughs in multimodality AIs. Not only do you understand the word 'cat' and the letters 'C-A-T', but you could look at an image and hear the sound 'meow' and recognize all of those words; all of that information is aligned to the same place in your brain. And we can now do that with all kinds of different modalities, which is very important to you. We made huge breakthroughs in reasoning capabilities, to be able to decompose through composition. Break down a problem we've never seen before into routine things, and through that composition, solve problems step-by-step, reasoning through hard problems. The ability to do multimodality reasoning and to be grounded by different sources of information is going to be a revolution even for your industry. It is clearly a revolution in ours. The idea that we would use multimodality sensors is very sensible. But the idea of a self-driving car stack that can think because it can reason through and experience a situation it's never experienced before. Reason through it step-by-step and be able to solve that problem, navigate through it. Incredible capabilities. It expanded the operating domain of self-driving cars tremendously. It's now the case that we are very certain we don't have to test every single car across every single scenario for that car to do well; just like us, we can now have a car that can think and be basically intelligent.

These techniques have made, and of course, agentic capabilities – the ability for agents to reason, use tools, work with other agents – completely revolutionary. And so these breakthroughs, in the time that I've been here, are permeating your industry, permeating life sciences – some of the most exciting work that I've seen in a very long time. And so today we announced a very important partnership. Before I get there, let me say a couple of things. We announced, of course, some of the work that we've done with all of you. We've brought an accelerated computing platform. But on top of that are a suite of libraries that we're very proud of. Parabricks for gene sequencing. MONAI, an open-source platform for medical imaging. And one of the most important ones is BioNeMo, a platform that understands geometric structures like molecules and proteins. These platforms are used by many of you in the room, and I'm very grateful for that.

Several announcements were made, and before I say that, there are so many partners here – a couple of hundred different companies – including pharmas, hospitals, or startups. There are startups in robotics, surgical robotics. There are startups in robotics labs. There are agentic AI companies here, helping with healthcare diagnostics and also some really cool work being done by AI scientists. Part of being at the JP Morgan event is that large companies meet small companies, and so many of them are doing revolutionary work. I'm so grateful that all of you have chosen the NVIDIA platform to work on. Our platforms ended up achieving some really great results. MONAI has been downloaded some six million times. We achieved the Guinness World Record for gene sequencing. That's cool. I've always wanted to be in the Guinness World Records, so that's cool. The vast majority of the world's structure prediction models are built on NVIDIA today. And so, I'm really proud of that. And on top of the BioNeMo platform are a whole bunch of pre-trained models. You use it for data processing. You use it for training these biological models. You use it for fine-tuning. But we also have a whole bunch of pre-trained models and a bunch of data that you can start with, and you could apply your data to fine-tune your molecules. Some of the models that we've created, participated in, and jointly developed are LaPorteina for protein design, ResNet for molecular synthesis, Kermit for predicting toxicity, and Evo2, a DNA foundation model. These foundation models, of course, start with us trying to learn the representation of proteins so that we can create a foundation model for protein. But the moment and time when we're going to learn a representation and create a foundation model for cells is just around the corner. The multi-domain systems and CodonFM for RNA design are making really terrific progress.

And so today we announced a large number of partners that are working with us in BioNeMo, and I'm very grateful for that. And we also announced a really landmark partnership with one of the most important companies in the world and a really great friend, Dave Ricks, and Lilly. So, I won't tell you more about it. I'm going to let the two of us describe it together. Dave has been the CEO of Lilly since 2017. And in the context of Lilly's history, it's a 150-year-old company. He's been in the company for 30 years. So he's basically a new college grad in the context of Lilly. And I'm anxious to learn from him how he learned so much in just a short period of time. But he's been with Lilly now 30 years, and as you know, he has helped guide and build Lilly into one of the most valuable companies in the world, and surely one of the most important companies in the world. And so if you could join me in welcoming my guest, David Ricks.

Thank you, Dave, for being here.

So, Dave was an Eagle Scout and went to a juvenile delinquent school. Just to be clear, I was placed there as an accident. It wasn't. It was no, that was a very good school. It was very affordable. So, in 2017, you became CEO.

Yes.

My question is this: What was Lilly like and what was its vision for the future of life sciences then, and what is it like today, and what is your vision for the future of life sciences in that context?

Well, in 2017, we were almost 140 years old – just a year older than that – and had a pretty well-established company. We had been through a difficult period of time in our industry, and we'll get into this a little bit later. We are plagued by – as many people in the room know – the cycles of innovation that are actually longer than the reward cycles, on average. So you have this peak-trough cycle; you're peaking and troughing. In the troughs, of course, you either don't survive, you end up as the back end of a hyphen on another company, or you learn how to survive and do difficult things. I think it's true that Lilly is the only major pharma company that has not merged or combined to get through such a period. We've been through a few of them. So, I think we've developed a bit of a DNA for scraping by in these tough times. And one of the things that really stuck with me – I was a leader on the executive committee at the time – was that we went through our last cycle in 2010, 2011, 2012. You have to be so relentless on invention because that time cycle is brutal. When you have a patent cliff and you have nothing to replace it, you have to rescale your whole company. And imagine doing this every 10 or 15 years; it's impossible to get momentum. People leave, you lose inherent knowledge, etc. So, we set about to do that. And I think that problem can be attacked two ways. One, you can say, 'Okay, we'll just have better ideas.' But as you may know, that's difficult to sustain. Even if you have a good idea, everyone thinks you're smart. They think about that about Lilly now. But it's hard to sustain. So, of course, we worked on that – more invention. But the more important thing we did was speed up invention. So we systematically took apart the R&amp;D process – literally every step, and there are hundreds of steps from candidate selection to first approval – and we squished the time. Still today, Lilly is probably about 40% faster than the next scaled pharma company on average across all therapeutic areas, so we can invent things inside the patent cycle.

Yeah.

Then you can start to grow.

Yeah.

So I think that was a notion in 2017 which we've actualized along the way. Then, of course, we did a lot of things to drive more invention. We were lucky enough to be early on an idea called GLP-1 in 2006. We launched the first one in the world.

Never heard of it.

Yeah, we fiddled around. Is it doing well? If it weren't for you, it would be the most important idea in the stock market. But it's a pretty good idea for mankind. We fiddled around with it for like 12 years.

Sounds like a chip, GLP-1.

Yeah, it does.

GLP-1. Is there a two coming?

There's a three coming. So there is a GLP-2 that's actually a real protein.

Is it really? Okay.

It's a protein. It sort of does the opposite. But you don't want that. What we've done is combined two hormones.

Very small market. I've got to tell you.

That's right.

Extremely small. I don't know healthcare, but I'm guessing people should sign up on GLP-2 now because tirzepatide, two proteins fused together, is a technology we've developed too. And there's a triple-acting one coming next year, in 2027. So that'll be pretty interesting. But anyway, we caught that wave. Our competitor innovated into obesity. We chased and executed, I think, quite well to become the market leader last year. So we not only now have an engine that's faster, we have a tremendous success cycle with this one idea. The challenge before us now is how do we find another success cycle before that one runs out – hopefully a lot sooner than it runs out – and get exit velocity, which really no major company in our industry has had. They've just had these cycles.

So, you said something earlier, and I have several of my employees here, and they hear me say this all the time. The fundamental purpose of the CEO is to create the conditions by which – our job isn't to create ideas. Our job is to create the conditions by which great ideas can systematically arise. What you just described is essentially Lilly with wisdom – that you have to create the conditions by which these great inventions can happen. One of the things – we've spoken before about the early days of NVIDIA getting into AI – and I would say that without exception, probably the single most important thing that we did was investing in the infrastructure, creating the conditions by which amazing AI researchers can come to our company and great inventions could arise. Today, we're quite silent about this, but people are increasingly discovering that over the course of the last 10 years, one of the best decisions that I made in the beginning was, at the time, we couldn't afford it. But nonetheless, I built one of the largest supercomputers in the world for NVIDIA to use. At the time, I had nobody to use it because NVIDIA had very few AI researchers. But the problem is, if you don't have AI researchers and therefore you don't have the instrument, you'll never have the AI researchers because scientists need the instrument necessary for their science. If you want to attract the world's greatest particle physicists, if you don't have a particle collider, you're going to have a very hard time doing that work. And so I came to the conclusion that the right answer is to create the conditions for great AI work to be done. I built that supercomputer, and we attracted some amazing people. Today, we do frontier work in physical AI, biological AI, and robotics AI. The work that we did in self-driving cars is revolutionary, which led our conversation to the idea that AI is starting to make enough progress that we might be able to apply it to tackle some of the most extraordinary challenges of humanity, which is biology.

Yes.

And the two of us thought it'd be amazing if we had the largest computer company in the world and computer science company in the world partner with the world's largest life science company. And it's as if we created this lab where we are essentially one company, combining all of the best amazing things together, which led us to our announcement today.

Yeah.

And so exciting.

Today we announced it.

And as you know, there are like four parts to this. We bought a bunch of chips, and we're building – I think it'll be finished this week actually – the largest dedicated on-prem biology supercomputer in the world. That'll be in Indianapolis, which is the world center for biologic discovery, by the way.

I was going to say earlier, because of the selection of Lilly's headquarters, it is exactly the reason why it has never merged with anyone.

Maybe so, that could be true. That could be true. There are a lot of artifacts with that.

Yeah. I think that seriously, there's something to like if you manage to make it all the way.

Yeah.

If you manage to make it all the way, and you're a discovery chemist or biologist, you really aren't going to leave, right? I mean, you made it all that way. You're going to stay. So, we have great retention. Anyway, we're building this huge system, so we have massive compute. Dave's invited me to visit him many times. He's never.

Actually, you did come in 2018. I don't know if you remember that.

Yes, I did.

Yeah.

Actually, just as a sidebar, that was the first time we met, and you gave a talk to our management team – a room about this size – about AI in 2018.

Yeah.

And I guess I was lucky enough to be in the 100% of the audience I could see. I could see it in their eyes: 'Nonsense.'

Honestly, it blew my mind. What you said blew my mind to the point where I spent several months reading about some of these things, which sounded like science fiction.

Yeah.

And now it's fact.

Yeah.

It's incredible what you built, and it's great to partner with NVIDIA on this. So, with the supercomputer, we're going to put together a research team here in the Bay Area. So if there are any smart scientists or computer scientists who want to work at the center, it'll be a joint Lilly-NVIDIA AI lab. We're going to develop new data because, as anyone who knows about this problem understands, you can train models, but if the data is an inch thin, you don't get very far, and biology is largely unknown. So we need to create massive experimentation for the purpose of training machines, and then we need to build on the work that NVIDIA has done with the models you've created to ladder up to even more sophisticated predictions.

That's right. So, super exciting! And so, one of the important things to understand about AI is that it's easy to think about it as a multi-layer cake. At the lowest level, you need some energy for these computers, and then of course, you have the chips and the computers. You have the infrastructure layer. That infrastructure layer is about how you cause this computer – it's kind of like the operating system of AI. How do you cause this computer to learn, process the data, learn? How do you guardrail it? How do you fine-tune it? How do you teach it? And so that layer is kind of like the HR department of AI.

Only they tell better jokes.

Exactly. And so that's the infrastructure layer. The layer above that is the models.

Yeah.

And the layer above that are the domain-specific data and flywheel. And one of the areas that's really exciting is the idea that we would be able to train models, synthesize proteins or chemicals, go put it into a robotics lab, collect more data, and then take that data back into our model. This flywheel of data generation – or model protein generation – using AI, collecting ground truth experimentation, and then putting that scientific flywheel on steroids. That future is just incredibly exciting. So, we're systematically bringing together some of the brightest minds in the field, in the domain expertise of drug discovery, and some of the brightest minds in computer science. Together, between the two of us in our co-innovation lab, we'll have essentially every layer of that cake and put together, hopefully, a blueprint for what is possible in the future of drug discovery.

I was going to tell you this. I was going to tell you earlier. I was going to tell you the story from 40 years ago. So, I guess 43 years ago, I was the first generation of engineers where the concept of computer-aided design was invented. Before my generation, my managers, that generation of engineers, would design a chip, and it would be a hit, but they would go several years without another hit. Then they would design another chip, and it would be a hit, and then they would go several years. It works now.

Exactly.

Exactly.

And our generation came along, and we were able to represent the transistor, the logical gates, the functionality. We learned the representation and described it in software. We did that 43 years ago. Finally, a computer could represent your domain and accurately simulate it. It's right to do as much in situ, in silico, as possible. And so today we design massive chips. 15,000 people come together to design a computer system. And we just taped out Ver Rubin. Billions of dollars of R&amp;D goes into it. The computer when it's done is three tons – a million and a half parts. And six brand new chips, 220 trillion transistors. I mean, it's gigantic systems. 15,000 people coming together, and that computer is going to work the first time. It does exactly what we expected, and every single generation we build upon the last generation. Every single generation we build upon the last generation. I think your time has come for that.

Yeah.

Finally the computer – a million times, a million times, a quadrillion times of computing power later. I think finally we might be able to represent one of the hardest problems in the world, which is human biology. And I'm really hoping that your industry moves from drug discovery, which is kind of like wandering around the forest looking for truffles. Literally, as a sidebar, we used to have a department of soil discovery. Seriously, we would send people into tropical forests and scoop up soils and bring them back to Indianapolis.

Uh-huh.

And refine out what became antibiotics. In fact, the most important antibiotic in the world is still vancomycin, the last resort antibiotic in the hospital. We couldn't run hospitals without it. It was discovered in Borneo in a soil sample by Lilly.

Now, how did they know to go there?

They would just go to exact locations because fungi produce tools to fight bacteria, so they'd dig in the soil and discover these naturally occurring defense mechanisms, refining them into drugs.

Huh.

But that is true drug discovery. Okay, when you think about it, right? That's like you could get malaria doing that job! That was, and that was in the '50s. That was 70 years ago.

Well, see, now your job gets to be just like my job. You never have to leave your office.

There we go. Do it all in silico.

Yeah. So, I think that's what really excites me. The concept that we could have computer-aided drug design.

Yeah.

And this is going to be, of course, incredible science behind it. It's incredibly complex. Human biology is incredibly complex, and it's still going to be a decade yet. But I really think that this announcement between us could be a blueprint.

The start of something. I hope you're right. I mean, we need it, right? I think if we think of all the unmet needs left at a conference at JP Morgan, you're reminded of the incredible pipeline of the industry, but most of that is sort of chipped out of stone – it's hard work. And especially, occasionally we can harness systems, like when monoclonal antibodies came around, we basically hijacked biology's way of making solutions to infections and other things. But mostly, what we do is really empirical, chipping away and very difficult. Each small molecule discovery is like a work of art. There's only one of them, and one brush stroke, and it's wrong. If we can make that an engineering problem, versus this sort of discovery, artisanal drug-making problem, think of the impact on human life.

The first chips that I worked on, my first generation of computers, were quite empirical. There are some rules that we used, and we apply some intuition. We have no clue how it's going to perform. We know that it's going to perform better than the last one we built because we made mistakes, so we could at least correct those mistakes, and we'll have more transistors and more of everything. So it's going to do better.

Yeah.

However, the functionality of it is unknown. Its full functionality is unknown. Its performance is completely estimated. Today we know the functionality of the systems we created down to every single bit. The performance we can measure. We simulate everything.

Yeah.

And so we know exactly what we're going to produce. I really believe that that could revolutionize the future. It would make that come true even for a part of human biology.

Yeah, that's right.

And so, tell me, GLP-1 – you were saying that it's really in its third phase.

Already.

And where does it go from here? What happens? What other things can you use it for? How could it change everything?

Well, I think as it turns out, obesity is a key lynchpin driver of chronic disease in adults. Like a lot of things in evolution, most of today's ailments were concerns in our evolutionary past, but we evolve much slower than our environment, so we're maladapted to the modern world. And obesity is one of those things. We grew up in a world of scarcity. Sounds like you grew up in a world of scarcity, but most people here didn't. Our ancestors did. And so, that's behind me. There was no need for an off switch on hunger.

The word is abundance now.

Abundance. Yes.

And we live in a world of abundance: abundance of intelligence, abundance of productivity, abundance of those kinds of things. And I don't know what you were thinking about, but my life is surrounded by abundance.

But unfortunately, we're all in caloric abundance now. And there was no need for us to wire in an off switch, evolutionarily. So, that's why we have obesity. And that leads to many chronic diseases that ail people and probably shorten life. So, I think by having a pretty effective set of tools – going to get more effective, and I'll get back to that in a second – to really help people manage that, to create an off switch synthetically in a way.

Yeah.

We can downregulate a lot of diseases, over 200 chronic diseases.

No kidding.

So, the two big evolutions that are going to happen in the next 24 months are real progress on more choices. So, GLP-1 is one peptide, but it's in a family. And by combining two in tirzepatide – GIP plus GLP – we see we can get better performance and better tolerability. I think you expect more of that kind of thing in the future. So within this super family of proteins, we can harness their combined strengths to really have much more tolerable drugs that are even more effective – effective in the maintenance phase, effective in inducing weight loss, and for different patient characteristics. That's coming. As I said, just reducing weight loss has so many downstream benefits. And that's the second thing, which is use cases. So, we know you lose weight. If you take our Zepbound today, you'll lose 23% of your body weight on average. But what we're starting to uncover is a series of obvious things like reduced heart attack and other metabolic systems that improve diabetes. Pre-diabetes conversion to diabetes drops by 93%. Imagine if we treated the country, where we have 70 million people with pre-diabetes, with Zepbound, we would literally have 93% less diabetes in our country. That's a profound finding, and hopefully with the government access deal we signed with the Trump administration, we'll be able to do something like that. But there are many now non-obvious, I think, use cases, or less obvious ones, inflammation being a primary one. So, being obese causes excess inflammation – not acutely like in response to an event, but chronically – and that's not good for you. It's not good for your cardiovascular system. It's not good for your joints. And so spontaneously in our early trials, people would report, 'Gosh, I've lost weight, but actually I can stand up from a sitting position for the first time in 10 years.' My knees don't ache as much. My back feels better. Or some people with Crohn's and colitis reported a kind of resolution of their symptoms. So why is this happening? It's because we're sort of taking down that chronic inflammation at a system level. So we're doing a bunch of studies. The first one read out last month on top of a medicine for psoriatic arthritis – a kind of arthritis – and it boosted the effect of that medicine by about 50% to co-prescribe Zepbound with it. So we're going to take that on medically, because that's how the medical system adopts innovations; they need the use cases. Perhaps similar to adopting AI technology, you need to prove the value in a particular setting. We're also starting a number of brain health studies right now, and we have a special-purposed GLP-1 GIP for brain conditions, particularly addiction, which is really a major modern problem. It turns out that for similar reasons – that these medicines downregulate your appetite, which is not really driven by our need for more calories but driven by other self-learned behavior loops – it can do the same thing or a similar thing for other harmful self-learned behavior loops like gambling, alcohol consumption, and smoking cessation. So, we're exploring all of these as well, which include – I hope it doesn't affect working too hard.

No, it's only the adverse ones we're trying to edit out.

Yeah, it's only the adverse ones. But it's a common pattern with over food consumption. Actually, there's a parallel for that. That's just a comment for all the startup CEOs. We've got a lot of startup CEOs in the room here. Be careful if you find your willpower is starting to diminish. Stop microdosing.

Yeah.

So, anyway, that's very exciting.

That's so interesting.

Yeah.

And then, I think on the horizon, people are working on much longer-acting versions, so you can take these less frequently. Of course, we'll launch our oral GLP-1 this spring, which I think is a major breakthrough, not just for convenience, but for global reach. It looks simple – our medicine in an autoinjector – but it's actually one of the most complicated drugs marketed in the world from a manufacturing perspective. And we have to do it hundreds of millions of times based on the current demand. We just launched in China, India, and Southeast Asia. There's a lot of obesity there. We cannot possibly meet all that demand with just injectable systems. So we need to get to Southeast Asia, where serious diabetes is a huge problem.

Huge problem.

Yeah.

And Southeast Asians sort of lost the genetic lottery of obesity because at much lower body weights, small increases in the amount of obesity trigger more diseases. So they need to use something to mitigate obesity. Hopefully diet and exercise. If not, they can use our medication, but we have to make enough. And having an oral form that's chemistry – it's not relying on protein synthesis and then putting it in these sterile injectable systems – just an oral pill. We can scale that massively. So that will launch this year as well. So, this one idea, you're going to ride this for another 50 years, right?

Right. We're hoping to. We're learning from you.

My gosh. That's... Hang on a second. I'm convinced. I'm convinced. GLP-1. It's the second best technology.

That's right. Exactly. Ours is not un... Blackwell. Blackwell is number one. GLP-2. GLP-1 number two.

Ours is not universal to the entire economy, just to the human economy.

Yeah.

That's incredible.

Very exciting. And one challenge we have is how can we keep inventing things that are better and better, enough that people will pay for them, to improve beyond the patent cycle.

But has there ever been a drug? Has there ever been a life sciences technology that has benefited humanity so broadly?

The only other class of drugs I'd say that did something like this, I alluded to earlier, is antibiotics. The discovery of penicillin invented modern medicine. If we subtracted antibiotics from our lives, we couldn't have modern dentistry.

Yeah.

We couldn't have surgeries. We couldn't do it. So now we take that all for granted. But when Fleming self-dosed this weird mold he grew in his lab, that was the start of a major wave. And that lasted into the '90s. So that was a 60-year cycle with 100-plus new medicines. I think this could be like that.

Yeah.

Which would be profound, but this is not for an acute infection. It's for chronic disease of the modern world. That's what we're affecting.

Well, Dave, did you ever realize that you were going to have such an easy job?

My wife asked me that a few times. Like, 'Why aren't you working?' One incredible discovery, one incredible thing. You were just running around the forest, and you discovered this thing called GLP-1.

Yeah, that's what I've imagined. You're digging up stuff and you found this incredible truffle, and it's solid for 60 years.

Yeah.

Yeah.

Actually, what's the history of this? So, it goes back to the '70s, and German scientists discovered this thing called the incretin effect. We call these GLP-1s part of this incretin family. These are hormones excreted by our gut which signal the rest of the body that you're fed, and we overboost those – and that's what is happening. But he observed that if you give sugar orally versus intravenously, you get a very different insulin response. Insulin is like the opposite. It stimulates absorption of sugar. It was slower if you give it orally. And so that's what's called the incretin effect, which was the first insight that somehow your body is doing something different when the gut is involved and when it's not. And that then led in the '80s to the discovery of GIP first, then GLP. Those are the two parts of Zepbound, and later, a whole another set of hormones. But one of the things I hope we can crack with our supercomputer and our team is that here we had targets, but it was really difficult to drug. The half-life of the native human form of GLP is like seven minutes. So to give that as a medicine – the native peptide sequence, which was identified in the '90s – you'd have to walk around with an infusion all day and all night. So that doesn't make for a product. It wasn't until we figured out how to extend that life first to twice a day, then to once a week, and now people are working on monthly and even beyond that, that we could make that an effective product. So one thing in AI drug discovery that is really working is this ability to create massive combination possibilities and then test those in silico and filter out good ideas. We're doing that at scale now. We can do that at even bigger scale with our collaboration. The other side is discovering. So that's the key to discovering the lock. Can we find more biology targets using AI? That is really the holy grail, because if we put those two things together, then we can model the whole system at once. Could be super exciting.

Yeah.

One of the things that Dave really wanted to do was to put the AI lab, the co-innovation lab, here in Silicon Valley, and even close by in AI city. San Francisco is really the epicenter of a lot of AI researchers, and we have an office here. So this is going to be either in South San Francisco, which is really the biotech hub of the Bay Area, or we can do it up here.

That's right. We want to go where people want to live.

Yeah.

Well, San Francisco is pretty cool.

It's cool.

Yeah, it's cool as well.

Yeah.

Yeah.

I've heard from just one other person.

We're very adaptive. We used to be good at basketball, but now we're good at football.

Uh-huh.

And so, we used to be good at chemistry, but now we can be good at AI.

Well, you're just good at suffering.

Yeah, we're good at something. That's true. Better than the alternative.

Yeah.

Yeah.

It's incredible.

And so, GLP-1 beyond – one of the things that a fair amount of Silicon Valley is talking about is longevity and aging.

The absence of...

Subtracting aging. And so, tell me, what is the technology behind that? Is it?

Well, it's an interesting topic. Obviously, it's attractive to a lot of people, because who wants to get old? Sometimes I just want it to be over. There are a number of... Yeah, I get that too. There's a lot of biology on why individual cells expire, and you can extrapolate that to cell systems, then organs, and then potentially the whole organism. But as we were talking offstage, that is not really a problem we work on that way. So that idea is essentially, can we extend the maximum shelf life of a human to something beyond what it is under perfect conditions? So let's just say under perfect conditions we can live up to a hundred years, and then for maybe good reasons, the system shuts down, right? I think it would be a weird world if people lived forever. Why would we reproduce? How do we evolve? There are a lot of problems with that kind of thing, even philosophically. How does nature fix that original design? Yeah, philosophically though, we would have a very weird world, I think. But I understand why people pursue it. We're more focused on a more practical problem, which is: if the maximum shelf life is 100 years, how do we get more people a better shot to get that full life? And the way we do that is by knocking out disease. So the reason people perished, if you look at life expectancy in our country in 1900, it was like 46 years old for a male, and the biggest factor there was child death. So you lost life because you died when you were young at a pretty high rate, mostly from infection. By having antibiotics and vaccination and other tools to manage childhood disease, that quickly shot up. From 1960 until now, we've added about 10 years of life expectancy, mostly through chronic disease extension. Cancer care has improved dramatically. Most companies in this room have had a big role in those chronic disease management, HIV/AIDS, and other new pathogens have been conquered. And that's, now we're up to almost 80 years in our country. Actually, the number would be more like 84 if it weren't for opioids and traffic deaths, which are exceptionally high in the United States – both of those.

So, self-driving cars can help with one of those.

Maybe GLP-1s will help with the other, because we're studying opioid addiction as a solution there.

But we chip away at it this way. And of course, as people live longer, the incidence of new maladies of aging rises. So the next frontier for us beyond GLP, that I'm really excited about and interested in, is dementia and diseases of the aging brain. Because as the rest of our bodies are able to carry us into our '80s and '90s, this is something we haven't really figured out how to address. For quality of life, but also quantity of life, that's going to be an important frontier. We're spending a lot of effort in that area. We've got some exciting programs running now in studies, but I think through drug discovery – simulating brain tissue and how to look for new targets and the interaction between targets we don't understand (there's inflammation plus protein misfolding happening in the aging brain) – perhaps we can discover something really exciting and new. If you take a step back and look at our co-innovation lab, the first thing we have to do is set up the computing platform for the researchers to do the work. And so we have the computers, we have the infrastructure layer, and we have BioNeMo, and we have a whole bunch of models – models and model architectures we've already invented. We'll get our scientists together, and they can start collaborating in that particular area, just building the foundations. But if you had a wish list for the researchers – I know that, and certainly it is the case with me. I try to influence the researchers' direction, but I try not to be directive.

Yeah.

And obviously, the reason for that is because we don't know what we don't know, and we don't know what can be discovered. There are many things that are discovered that, quite frankly, we didn't even know were possible. But once it's created, our innovation brain can kick in, and together, we can try to figure out how to bring that to the market. But if you had a direction that you would like to set them on, in what direction would you hope that they do some research?

Yeah, I think there are like two basic problems, and I think within these we'd have to narrow the scope to make progress and feel achievement. The first one, there's a lot of momentum in our space already, which is what I talked about: the drug design, engineered drug design. You could argue a lot of drugs these days fall into that category. You know the target because it's been around and well-profiled, and you're better customizing the key to the lock. But there are new modalities that have emerged – RNA, gene therapies, etc. – that really haven't been optimized because they haven't been around as long. So I think that whole suite of problems around drug engineering, drug optimization, is pretty tractable, and I think the NVIDIA scientists, coupled with ours, could make a lot of progress pretty quickly there. That solution, by the way, would be highly amenable to our Tune Lab kind of interface we've built.

Yeah.

For all of our biotech partners as well. Better drug making through in silico, engineered design. And just so you guys know, for anyone who doesn't know about Tune Lab, this is a platform where Lilly and startups or third parties could work together, both contributing data.

Yeah.

To advance a particular space, and it's built on top of a platform that is called federated learning. It's called NVFlare, that we contributed to, so that developers and researchers don't have to aggregate all of your data, co-mingle your data, but you could still train a model together so that you can benefit together. The thing that's been really exciting since our announcement – all day long, the number of startups have been really excited about Tune Labs and co-innovation and how they could be involved, just coming out of the woodwork. So I think the vision you have for Tune Labs and the work that you did in building up Tune Labs is completely visionary, and it makes possible collaboration for AI researchers that are not in the same company. It's very hard to data, protecting intellectual property, but the process of improving their idea improves the training of the model itself. So we all gain by participation. There are no fees. We do curate it. So there are legitimate biotech projects, but we will add the product of our work together to the Tune Lab interface. And so not just Lilly scientists can benefit, but many biotech scientists. The other side of the equation, of course, is the target. Here, I think we need our robotics effort to really kick in. Why do we have more targets, and why do we understand the targets we have better, which are probably structurally more complicated than we understand? That's one of the reasons drug development fails: we think we have the target, but we don't really understand it. That's because we need massively more amounts of experimental data on specific, good targets. So I think here we'll work with you on flushing out. We already have one robotic lab running wet lab, but we'll build more. We can have them running 24/7, experimenting around a target space to really fully profile that, and then couple that with those engineered drug designs. So that's a little bit harder problem. It's more empirical, but I think machines are made to work day and night to solve this problem. And that flywheel is going to fly. I think, Dave, if you look at some of the advances that we've had in other domains, the first thing is you need the flywheel to eventually land at ground truth. So, you have to have physical world experimentation, collect that data. And you close the loop that way. Eventually that model becomes sufficiently good, that foundation model becomes sufficiently good, and you could teach it how to generate – to be generative. Eventually, there's a model that is being tested against another model, and this other model is the world model or the target model. The target model, along with the model that you're training, runs in a closed loop, so essentially, the lab is another model.

Yeah.

And so you eventually have to ground it again by producing and synthesizing the proteins and collecting real data. But we get ourselves in a synthetic data flywheel, and that synthetic data flywheel is incredibly effective. I don't think that's been attempted in our industry at scale, and I think we'll do that here. But I think really, taking a handful of targets which we highly suspect will be useful in key diseases, and really doing the full profiling of those in robotic wet labs to train the data set, and then use the machines to fill in the space and make better drugs, because we understand this is so exciting. It's singularly true that finally we're going to have a lab where the expertise and the scale of that lab is going to be sufficient to attract people who really want to do their life's work in that intersection.

Yeah, we'll be so excited.

So I'm super excited about that. And so one of the things that is really cool about this conference is large companies and small companies getting together. This year, AI scientists – there's a company I met today. We've been working with them for some time. I hope they don't mind that I mentioned their name. Eddison is really terrific.

A foundation model company is going to build both the life sciences lab and the AI lab, or the factory—a real robotics factory—and a large-scale system. LILA and other companies are incredible; they're probably in the audience.

What are some of the companies that you've seen? Robotics labs, AI scientist companies. Of course, Agentic Healthcare AI assistance, the work that Abridge and Open Evidence are doing, is really cool. What are some of the areas that you've seen that are really cool?

I think for AI, the most tractable problem now that you're seeing more and more is healthcare service. This is not as complicated as what we're talking about here today, but rather, how do you replace human-level service with agentic service, AI service? It seems so obvious for what is the least productive part of the entire economy to adopt AI. But there are a lot of frictions for that. A lot of our discussions are, &quot;How can we collaborate?&quot; We run what I think is probably the largest direct pharmacy platform in the country, Lily Direct. It's only a year old, but it's annualizing close to a billion dollars a quarter right now—four billion a year just selling pharmacy. People want to say, &quot;Can Lily work with us to use your market weight to force adoption and work against insurance companies?&quot; Let's be honest, they're not into change. Physician groups are frightened by some of these technologies. But we really do need to make the US healthcare system more efficient. In doing so, we can actually have more room for innovation, more room for adoption of cutting-edge medicines, and maybe more accurate and comprehensive workup of people.

That seems inevitable, but what can we do to speed that up and really harness that? There are a lot of new modalities, as I was mentioning earlier, to drug targets. In the last 10 years, without AI, the industry's productivity on new modalities is accelerating, and that's exciting. Yet it's early days, so a lot of companies are combining new and old modalities into bifunctional medicines—that's a hot field where you have a targeting part and then a warhead part, say, to kill cancer cells. Even just refining how we get these medicines to the right tissue is an important problem, and there are a lot of interesting new, different approaches happening that I took meetings on today that were pretty interesting to me. That's the drug-making side, and I think AI can help us accelerate that, but a lot of smart people are working on those problems. Of course, a lot of people want to talk about GLP1s—that's my life.

It was good you said small companies and big companies getting together. Here, we're the small company and you're the big company.

Cut it out.

And we're getting together.

Cut it out, cut it out.

Lily probably had a reputation 10 years ago when I started, around 2017, as a little bit of a sleepy Midwestern company. But here's a fun fact for the computer people: the first approved biotech product made by a living organism, a medicine made in the most modern way, was a Lily product, Humulin, which we collaborated with Genentech on. Then, 12 years later, we bought the first supercomputer in the pharmaceutical industry and put it in Indianapolis. It was a Cray supercomputer called Big Red.

Our company logo is red.

Big Red. Very clever. We designed the first approved medicine designed on a computer on that thing. It's called insulin lispro, which is Humalog. It's still used by Type 1 and Type 2 diabetics globally today by playing around with amino acid sequences empirically.

Always trying to convince me that Lily is cool.

We are cool. We are cool. We've been working with computers and the cutting edge of science and computer technology.

You had me at hello. At hello. This just makes tons of sense because it's a natural evolution of our company. So awesome.

It is so awesome to work with you and your team, and I am so excited about the work that we're about to do together. I can't imagine a more worthy, more complex, more exciting field to apply computer science to. For someone who's dedicated a whole career in basically one job of building computers, the opportunity to work with you and Lily and the scientists there in service of the next breakthrough can't be more exciting. I want to thank you for your partnership and for personally driving this. The two of us teaming up together, pulling together the might of our two companies, hopefully we can bend the arc of history and see if we can make a difference. That's super exciting.

That's so exciting to hear you say that. Thank you for helping make this come together. We're just getting started, but this could be a new day. If we can accelerate progress, even if we set modest goals, I think we can accelerate progress in a use case for computer technology that has to be the most personal and impactful for our country and for the world, and for an industry that really needs to find more ways to be more productive with R&amp;D dollars. It's a worthy try, but we're going to do more.

We're going to make it happen. We're going to make it happen. Ladies and gentlemen, David Ricks and the second most—I'm just kidding. Thank you. Thanks. Thank you. Great. Thank you. Thank you. Fun. That was fun to do. Thank you. Cheers.
                    </div>
                </div>
                
            </article>
            

            <article class="video-card" id="video-4">
                <div class="video-header">
                    <h2 class="video-title">
                        <a href="https://www.youtube.com/watch?v=jLVgGGz5bvk" target="_blank" rel="noopener">Ben Horowitz &amp; David Solomon on Why Scale Is The Only Thing That Matters</a>
                    </h2>
                    <div class="video-meta">
                        <span class="channel-pill"><img class="channel-icon" src="https://yt3.ggpht.com/hkiO7UAtALrbqOcewo4CIrbd0j8XDeWttKkdtihfX1emeV4iUMwjIe1KKn4zd6wT2OOwANDnIA=s240-c-k-c0x00ffffff-no-rj" alt="" loading="lazy"><span class="channel-name">a16z</span><span class="channel-subs">(245.0K)</span></span>
                        <span class="meta-sep">·</span><span>35:35</span>
                        
                        <span class="meta-sep">·</span>
                        <span>2026-02-02</span>
                    </div>
                    
                </div>
                <div class="tldr">The current macro environment offers a &quot;sweet spot&quot; for financial assets, driven by significant stimulus and a capital investment super cycle that's poised to drive strong M&amp;A and IPO activity.</div>
                <div class="summary-section">
                    <div class="summary-preview" id="preview-4">The current macro environment offers a &quot;sweet spot&quot; for financial assets, driven by significant stimulus and a capital investment super cycle that's poised to drive strong M&amp;A and IPO activity. Both Goldman Sachs and Andreessen Horowitz are strategically adapting to this...</div>
                    <div class="summary-full" id="full-4">
                        <h3>TL;DR</h3>
<p>The current macro environment offers a "sweet spot" for financial assets, driven by significant stimulus and a capital investment super cycle that's poised to drive strong M&amp;A and IPO activity. Both Goldman Sachs and Andreessen Horowitz are strategically adapting to this landscape, with Goldman focusing on scale and funding diversification, while a16z is growing its venture influence and actively shaping crucial policy for emerging technologies like AI and crypto.</p>
<h3>Current Economic &amp; Market Outlook</h3>
<ul>
<li><strong>"Sweet Spot" for Financial Assets:</strong> The U.S. macro picture is highly favorable for financial and investable assets.</li>
<ul>
<ul>
<li><strong>Fiscal Stimulus:</strong> Significant and continuously increasing, with recent legislation adding to an already stimulative environment.</li>
<li><strong>Monetary Stimulus:</strong> In a rate-cutting cycle, with a few more cuts anticipated.</li>
<li><strong>Capital Investment Super Cycle:</strong> Unprecedented levels of investment; last year, the four largest companies contributed 1% to GDP growth with $400 billion in spending.</li>
<li><strong>Deregulatory Wind-back:</strong> A shift from a massive regulatory surge, further stimulating the economy.</li>
<li><strong>Economic Resilience:</strong> The economy is hard to slow down due to this "cocktail of stimulus" and enormous financial leverage, despite average Americans feeling stress from 25-30% higher prices.</li>
</ul>
</ul>
<li><strong>Market Dynamics:</strong></li>
<ul>
<ul>
<li><strong>AI Productivity Gains:</strong> The market is "pulling forward" expectations for AI-driven productivity gains over the next 1-4 years.</li>
<li><strong>Geopolitical Fragility:</strong> Moving to a multipolar world, with higher geopolitical risks and increased volatility due to social media.</li>
</ul>
</ul>
<li><strong>M&amp;A and IPO Expectations:</strong></li>
<ul>
<ul>
<li><strong>Regulatory Shift:</strong> The previous "no" to M&amp;A questions from regulators is now "maybe," even for very significant deals, due to a changing regulatory environment.</li>
<li><strong>Projected Surge:</strong> Anticipated to be the "biggest M&amp;A year in history" and a significant year for IPOs, with many large companies finally going public.</li>
<li><strong>AI-Driven IPOs:</strong> The rapid erosion of competitive leads in AI (due to the ability to "throw money at the problem" with data and GPUs) will compel companies to seek capital through IPOs.</li>
<li><strong>FTC Uncertainty:</strong> Concerns remain regarding the FTC's aggressive stance, especially on big tech, potentially favoring IP transactions over traditional M&amp;A.</li>
</ul>
</ul>
</ul>
<h3>Goldman Sachs: Evolving for Future Relevancy</h3>
<ul>
<li><strong>Entrepreneurial Heritage &amp; Evolution:</strong> The firm was built "brick by brick" by entrepreneurial partners, maintaining a partnership culture even 25 years post-IPO.</li>
<ul>
<ul>
<li><strong>1999 IPO:</strong> Essential for long-term relevance, providing the permanent capital needed to participate in the global expansion of capital markets.</li>
<li><strong>Post-IPO Culture:</strong> Maintaining an aspirational partnership culture (450 partners, compensated relative to enterprise performance) while evolving from a small private partnership to a public company requiring top-down strategic direction for growth.</li>
</ul>
</ul>
<li><strong>Strategic Priorities for the Future:</strong></li>
<ul>
<ul>
<li><strong>CEO's Role:</strong> Owns firm strategy, ensures execution for growth, and manages big-picture strategic risks.</li>
<li><strong>Scale is Paramount:</strong> As an institutional firm, scale provides "enormous leverage and latitude" in mature businesses.</li>
<ul>
<ul>
<li><strong>Current Gap:</strong> Goldman Sachs has a $1.9 trillion balance sheet compared to JP Morgan's $4.5 trillion.</li>
<li><strong>Future Goal:</strong> Goldman Sachs aims to be "at least three and a half" times its current size if JP Morgan reaches six, necessitating growth beyond purely organic means.</li>
</ul>
</ul>
<li><strong>Funding Diversification:</strong> Reducing reliance on wholesale funding, a major strategic risk.</li>
<ul>
<ul>
<li><strong>Shift from Wholesale:</strong> Once the "largest wholesale funder in the world" 10 years ago, a position not desired.</li>
<li><strong>Digital Deposit Platform:</strong> Built from zero to ~$500 billion in total deposits, now funding ~40% of the firm, offering more stability than institutional wholesale funding.</li>
</ul>
</ul>
<li><strong>Core Values:</strong> Client Service, Partnership, Integrity, Excellence guide the firm's operations.</li>
</ul>
</ul>
</ul>
<h3>Andreessen Horowitz: Scaling Innovation &amp; Shaping Policy</h3>
<ul>
<li><strong>Founding &amp; Evolution:</strong> Started in 2009 during a challenging market, recognizing "the best time to raise money is when nobody has money."</li>
<ul>
<ul>
<li><strong>"Top-Tier" Strategy:</strong> Achieved top-tier status by offering a "better product" for entrepreneurs, enabling founders to run their companies as CEOs with enhanced brand, power, and access.</li>
<li><strong>Scaling for "Software is Eating the World":</strong> Designed the firm to scale and address a market beyond the traditional "15 significant companies" per year to potentially 150, necessitating a different organizational structure than traditional VC.</li>
<li><strong>Market Leadership:</strong> Now "the biggest," having raised ~18.3% of all U.S. venture capital in the last year.</li>
</ul>
</ul>
<li><strong>Future Ambition: Growing the Market:</strong> Inspired by Andy Grove, a16z views itself as responsible for growing the entire industry and ensuring technological leadership for the U.S.</li>
<ul>
<ul>
<li><strong>American Dynamism:</strong> Focuses on how the country wins technologically and remains competitive with China.</li>
</ul>
</ul>
<li><strong>Key Policy Agendas:</strong></li>
<ul>
<ul>
<li><strong>Crypto Policy:</strong></li>
<ul>
<ul>
<li><strong>Importance:</strong> A "profound breakthrough" in financial technology and society (property rights, business architecture for creatives, stakeholder capitalism).</li>
<li><strong>Past Challenges:</strong> Faced a "complete ban" by the previous administration through "abuse of power," including debanking and "wells notices" for private companies.</li>
<li><strong>Legislative Wins:</strong> Successfully pushed for the Genius Act and Stable Coin Bill.</li>
<li><strong>Current Focus:</strong> Advocating for the "Clarity Act" (market structure bill) to establish clear rules for classifying tokens (security vs. other assets), countering the "everything's a security" approach.</li>
</ul>
</ul>
<li><strong>AI Policy:</strong></li>
<ul>
<ul>
<li><strong>Existential Threat:</strong> Concerns that banning or infringing on AI development (e.g., regulating math) will lead the U.S. to lose the AI race to China, with "hundred-year implications."</li>
<li><strong>Key Protections:</strong> Advocating to:</li>
<ul>
<ul>
<li><strong>"Don't Regulate Math":</strong> Regulate the *applications* of AI (e.g., using AI for illegal activities), not the underlying mathematical models themselves, as models are not sentient.</li>
<li><strong>Prevent State-Specific Laws:</strong> Avoid 50 different state AI laws that would stifle innovation across states.</li>
<li><strong>Enable Copyright Training:</strong> Allow building statistical models over copyrighted works (not reproduction) to create smarter AI, acknowledging China's lack of copyright respect.</li>
</ul>
</ul>
</ul>
</ul>
</ul>
</ul>
</ul>
<h3>AI's Transformative Impact &amp; Operational Challenges</h3>
<ul>
<li><strong>Internal Adoption &amp; Productivity:</strong></li>
<ul>
<ul>
<li><strong>Goldman Sachs:</strong> Views AI as an "acceleration" of productivity for its professional services workforce, enabling more impact through tools and applications.</li>
<li><strong>Andreessen Horowitz:</strong> Aggressively automating non-preferred tasks, leveraging data lakes for insights, and enhancing customer support with AI.</li>
</ul>
</ul>
<li><strong>Reimagining Enterprise Processes:</strong></li>
<ul>
<ul>
<li><strong>Goldman Sachs (1GS 3.0):</strong> Focusing on "completely reimagining" fundamental operating processes across the massive enterprise to automate and make them more efficient.</li>
<li><strong>Strategic Investment:</strong> Efficiency gains create capacity to invest in growth areas; for example, finding $2 billion in savings could allow spending $8 billion on technology instead of $6 billion while maintaining returns.</li>
<li><strong>Challenges:</strong> Requires top-down leadership to overcome cultural resistance to change "empires" and navigate significant regulatory hurdles for new technology adoption.</li>
</ul>
</ul>
<li><strong>AI in Investing:</strong></li>
<ul>
<ul>
<li><strong>Limitations:</strong> Models rely on available facts, but major investment shifts often stem from "completely new and unexpected" events not found in past data.</li>
<li><strong>Potential:</strong> While models can quickly incorporate new information, it's "interesting to see" if they can outperform human investors, many of whom underperform due to biases.</li>
</ul>
</ul>
</ul>
<h3>Notable Quotes</h3>
<blockquote>
"The best time to raise money is when nobody has money." - Ben Horwitz on <strong>venture capital timing</strong>
"If you're in our kind of businesses, if you're attached to financial assets, this is as sweet a spot that I've seen." - David Solomon on the <strong>current macro environment</strong>
"For the last four years, whatever the question was, the answer was no. Okay. Now, whatever the question is, the answer is maybe." - David Solomon on the <strong>regulatory shift impacting M&amp;A</strong>
"With AI... if you have proprietary data and you have enough GPUs, you can solve like almost any problem. It is magic." - Ben Horwitz on <strong>AI's transformative power</strong>
"If you ban the technology... or ban or kind of infringe people's ability to do mathematics... then I think we're definitely going to lose the AI rights to China." - Ben Horwitz on <strong>AI policy risks</strong>
</blockquote>
                    </div>
                    <button class="toggle-btn" id="sum-btn-4" onclick="toggleSummary(4)">
                        Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>
                    </button>
                </div>
                
                <div class="transcript-section">
                    <button class="transcript-toggle" id="trans-btn-4" onclick="toggleTranscript(4)">
                        View transcript
                    </button>
                    <div class="transcript-content" id="transcript-4">
                        We were the largest wholesale funder in the world 10 years ago. There are a lot of things you want to be the largest in the world; wholesale funding is not one of them. We received a lot of criticism, like, &quot;Why are you raising money now? Are you stupid?&quot; It turns out that the best time to raise money is when nobody has money.

Last year, the four largest companies contributed 1% to GDP growth with their $400 billion of spending. M&amp;A and capital raising IPOs are driven by confidence. For the last four years, whatever the question was, the answer was no. Now, whatever the question is, the answer is maybe.

If you are in our kind of businesses, if you are attached to financial assets, this is as sweet a spot as I have seen. With AI, if you have proprietary data and enough GPUs, you can solve almost any problem. It is magic.

I have had the distinct pleasure of working at least indirectly for both David Solomon and Ben Horowitz and have a lot of affection for both Goldman Sachs and A16Z. If you haven't read it, I highly recommend reading the book *The Partnership*, which is written by Charles Ellis and chronicles Goldman's nearly 160-year history. I think the most remarkable thing about Goldman's history is that it is not a business built through a series of bank mergers, unlike many of its peers. It was truly a business built brick by brick by generations of entrepreneurial partners raising their hand, going off and building new businesses, whether expanding into Europe, starting the merchant banking business, or the wealth management division. Many of these business units became global franchises. I would argue that Goldman was and still is one of the most entrepreneurial financial institutions in the world. As I think about where we are in our own evolution at Andreessen Horowitz, I like to think that this is what Goldman Sachs must have felt like 50 or 75 years ago—a small group of entrepreneurial investors betting on a future.

Goldman stopped speaking to Sachs forever. They got very mad at each other over whether Sachs supported Germany in World War I. You actually remember your history, wow. Well, yes, a small partnership betting on the future with big hopes and ambitions. I'll leave it at that.

Well done, David. Thank you. Pulling on that thread, David, you have been at Goldman for over 25 years, having joined the firm, I believe, in 1999, just after its IPO. How has the firm evolved during your tenure? And maybe more importantly, what are you focused on to position Goldman for the future?

Before I start on that, first of all, it's great to be here, great to be with everybody. I just want to share one of the big lessons I have in my life: if you are joining a new firm that is a private partnership, do not spend six months negotiating so you carry over past the IPO date. Join before the IPO. It is a good lesson for all of you in private partnerships.

The firm is a remarkable place, and I really appreciate what you said about its entrepreneurial spirit. The firm was for a long time a private partnership. The thing about private partnerships is you have this mutual agency where people go off and do things. There is some structure that creates a collective each year or each cycle where everything comes back, and then there is a re-evaluation of the partnership shares, and you go off again into the future to do more. That served the firm incredibly well, and it stayed a partnership much longer than any other big Wall Street firm. I would say the firm stayed a partnership until the last moment when it absolutely couldn't be a partnership anymore because it needed the permanent capital to truly make it a relevant business. If the firm hadn't gone public in 1999, it would have missed the global expansion of capital markets and probably would look more like Lazard today than Goldman Sachs. The stewards of the firm at that point did an incredible job.

I think the challenge for us over the last 25 years, and the leadership team over the last eight years has really done an incredible job at this, working together to do this, is that somehow, 25 years after an IPO, we still have this partnership culture. It is highly aspirational every two years to become a partner of Goldman Sachs. We have 450 people who are compensated in correlation to how the overall enterprise does. The big thing that I am really proud that we, as broad leadership, have done is we have started to recognize that we are not a small private partnership, and you cannot be a public company and not grow and have some form of top-down strategic direction. That really gets the whole thing making the one plus one plus one plus one equal more than what the math adds up to. That has been a journey, and it has been bumpy. You were there for part of those bumps. I think we have navigated well, and I still think the principles and values that we sit upon as a firm – we really strive to be the most exceptional financial institution in the world. We do not always get there, but we strive for that, and we really sit on four core values of client service, partnership, integrity, and excellence. We try to live it, and I think the firm is in a really good place. In some ways, it hasn't changed at all in 26 years; in some ways, it has changed massively.

Are there a few things you are most focused on as CEO, looking forward for the next five or ten years?

One of the things I have learned—I was a banker and advised CEOs for a lot of my career, but actually owning the responsibility—is that one of my big takeaways from the last eight years is that it is very different than giving advice. I think the most important thing a CEO has to do in a big enterprise like this is to own the strategy and direction of the firm. I am focused on how we ensure we are executing toward growing the firm because I know we have to do that to perform on a relative basis. But then I am also thinking about and worrying about big-picture strategic risks that can make the firm less relevant, less successful, less important, or less competitive.

For us, I think there are two things the firm is really focused on. First, one of the things that makes the United States an extraordinary place is that we have the most extraordinary capital markets, the most extraordinary financial system, and the most extraordinary financial institutions. I would argue that the six most important financial institutions in the US are all US financial institutions, and there is no global institution that can compete in terms of its relevance in the world with the six most important US institutions. When you look at those institutions, there are different kinds. There are retail banks, more traditional 'banky' banks, which would include JP Morgan, Wells Fargo, Bank of America, and Citibank. They all have global businesses, but they are truly banks in what they do. They have retail platforms and retail businesses. Then you have two institutional firms, which does not mean they do not touch individuals in different ways, but Morgan Stanley and Goldman Sachs are both institutional firms. Goldman Sachs is a bit of an island of one in the context of how we are positioned as an institutional firm, and Morgan Stanley is a bit of an island of one in terms of how they are positioned.

Scale matters a lot. I just went through all those firms; the two smallest firms of all those are Goldman Sachs and Morgan Stanley. So when there is turbulence in the world, you always want scale. Scale in these businesses, because they are so mature, gives you enormous leverage and latitude. We continue to think a lot about scale, and we think out 5, 10, 15 years: how are we going to maintain a level of scale that makes us competitive? Ten years ago, it would have been unfathomable that Goldman Sachs could have a $1.9 trillion balance sheet, but at the moment, JP Morgan has a $4.5 trillion balance sheet. When JP Morgan is six, we are going to have to be at least three and a half. So, we have to think about how we can continue to create that scale because these are very mature businesses, and it is hard to truly build that scale purely organically. So that is one.

Two, funding. Funding these enterprises is one of the big strategic risks to these enterprises. These enterprises live on funding and liquidity. We do not have a traditional deposit funding platform. We have, and you participated in this, a very excellent digital deposit platform that now has over $200 billion in deposits. We also have about $500 billion of total deposits; 15 years ago, we had zero. So we fund about 40% of the firm's deposits, but deposits are a much more stable funding source than institutional wholesale funding like commercial paper. We were the largest wholesale funder in the world 10 years ago. There are a lot of things you want to be the largest in the world; wholesale funding is not one of them. So, that strategically is another thing we worry about.

These are big things on stepping back and getting away from the day-to-day execution and thinking 10, 15, 20 years, which, by the way, I will not be here running the firm, but it is still my responsibility to steward and chart that. In the short term, I am much more focused on technology across the organization and how technology shifts the way we do things, how we are rebuilding processes, operating differently while staying true to what we do.

Awesome. We are here to help with that today, too. Absolutely.

Ben, transitioning to you, you and Mark started the firm at an auspicious time in the wake of the financial crisis in 2009. It turned out to be a really interesting moment because it was the beginning of mobile and the rise of the cloud. It's funny, we received a lot of criticism in venture capital, like, &quot;Why are you raising money now? Are you stupid?&quot; It turns out that the best time to raise money is when nobody has money. It is very obvious when you say it that way, but the nature of investing is that people always want to invest high and always want to walk away when the market is low. It is just one of those things, so we got very fortunate.

Maybe you can describe the evolution of the firm since you started and what your ambitions are for the future as well.

The original idea in venture capital is that the fundamental thing you have to be is top tier, because if you are not top tier, then the best entrepreneurs will not take your money. There are times when the market is so blazing hot that you can be a less important venture capital firm and dump into good deals and make money. But in most times, if you are not top tier, you are going to go out of business. The difficult thing about being top tier is that historically, you became top tier reputationally. So if you are Sequoia, you invested in Apple, Cisco, Yahoo, and Google. It is really hard to make up that ground if you are starting in 2009.

The idea we had originally to get to top tier was to basically have a better product, a better product specifically for entrepreneurs. The venture capital product was great for LPs, but we thought mediocre for entrepreneurs. So we designed the firm to really enable a founder to build his or her own company and run it as CEO, which was not the common idea then; the idea was much more to replace the founder. A lot went into it, and because we were founders, we knew what that was. So we created a firm to give a founder brand, power, and access—all these things VCs said they did, but they did not have to because they were top tier; it did not matter. We did that, and that is how we got into a position to be a long-lasting firm.

The second phase was based on something Mark wrote in 2011 called &quot;Software is Eating the World.&quot; The idea with &quot;Software is Eating the World&quot; was that if you looked at venture capital up to that point, there were studies that said in any given year there would be approximately 15 technology companies that get to $100 million in revenue, and those would be the companies worth money, and nothing else would be worth money. So the whole venture capital &quot;sport&quot; was how many of those 15 can you get into? Now, if software was going to eat the world, we thought, maybe that 15 is going to be 150. And maybe one of the features of a venture capital firm is going to be that you will have to be able to scale it. Traditionally, I remember Dave Swensen, the great Dave Swensen, RIP, who ran the Yale endowment for years, saying to me, &quot;A good venture capital firm is like a basketball team, five, maybe six players, that's it.&quot; But you cannot address a market where you have to be in 150 companies with six players. So how do you organize, how do you scale, how do you design the firm so that you can get to the whole opportunity and yet still be really good at investing and not have more than five or six people talking about a deal? That was phase two, and that is when we somewhat left the building in terms of what was going on in Silicon Valley, because nobody else was thinking that way.

Last year, about 18.3% of all venture capital raised in the US was raised by us. So we are now from tier one to the biggest. Going forward, what I think that looks like is—and I get a lot of this thinking from my old mentor, Andy Grove. It was actually at the end of his life, but one of the things he said to me that I always remember (for those of you who do not know him, he ran Intel and got it through that great memory crisis and changed the company, probably the greatest tech CEO we have seen) was something very obvious but also profound: if you are the leader of an industry, then the growth of that industry depends on you. You have to grow the market; nobody else is going to do it. That responsibility is on you. He really took that seriously at Intel. So when I think about what we are as a firm, a lot of it is that it is incumbent on us, and a lot of the work we have done on policy for crypto, and things we are doing internationally, things we are doing on American dynamism, is about how we win, not just Andreessen Horowitz, but how the country wins technologically. How do we continue to compete with China? How do we remain relevant in the next hundred years like we were in the last hundred years? And that drives backward into how we think about how we have to develop.

Awesome. Maybe we will transition just a little bit to markets. David, how would you describe the macro environment? What are you hearing from the CEOs you work with and advise most closely?

First, Justin, Ben, and I were talking about this: if you are in our kind of businesses, if you are attached to financial assets or investable assets, this is, I have been doing this for 40-some years, as sweet a spot that I have seen in terms of the macro picture. Now, that does not mean there are not all sorts of difficult, complex things going on in the world, but I think we are at a moment. Let's just be here in the United States for a minute. We can go around the world and talk about anywhere you want, but let's just start here in the United States.

The combination of the significant and continuously increasing fiscal stimulus—and by the way, the big beautiful bill that started in '26 just adds more to that. It is not that we were not in a very stimulative place; we just added a whole bunch more. We have fiscal stimulus, we have monetary stimulus because we are in a rate cutting cycle. That does not mean I think we are going to see many more rate cuts, but we are probably going to see a couple more. We are in a capital investment super cycle, like something we have never seen. Last year, the four largest companies contributed 1% to GDP growth with their $400 billion of spending. We are in a deregulatory unwind cycle from a massive regulatory surge during the last administration to a deregulatory wind-back that is very stimulative. All these things—it is just such a cocktail of stimulus that it is very, very hard to slow the economy down.

While average Americans definitely feel a lot of stress because everything is more expensive—you could talk about inflation going from nine to three, but the bottom line is everything is 25% to 30% more expensive, and that is the way Americans feel it. There is pressure, but at the same time, there is enormous financial leverage that keeps the economy going and makes the economy a little bit more versatile. So, if you own monetary assets or investable assets, if you are around growth and technology, this is a pretty prime environment. I could give you a hundred things that can set it off. Last April, if you were in Davos last January, people felt the same way, and then in April, we had a speed bump, but it was a short speed bump.

I think there are two things that have the market moving ahead. One, you have a president that, if you look at the speed bump last April, he marks to market to that market every single day. If the market is going in the wrong direction, he has no problem adjusting very, very quickly. Number two, the productivity gains from AI investment and putting it into the enterprise and having the enterprise pick it up. The market is pulling forward a lot of what they expect to be delivered over the next one, two, three, four years. So that is a pretty prime macro environment.

Now, geopolitics are much tougher. We are moving back to a multipolar world, and the risk of a geopolitical problem that really slows down growth is much higher than it has been for the last 10, 20, 30 years since the wall fell. The world is fragile. Social media creates a lot of volatility and division. The way people absorb information, the way information moves, makes the world faster-moving but also more volatile. So a lot can go wrong, but at the moment, from a base economic perspective, that cocktail of stimulus is pretty powerful.

Maybe a follow-up question for both of you: do you expect to see a lot of M&amp;A or IPOs this year? How are you advising your CEOs? We have a lot of them in the audience.

It is a fact-based answer. We had a very, very tough regulatory environment. M&amp;A and capital raising IPOs are driven by confidence. If you have a tough regulatory environment, that is something that affects confidence. From an M&amp;A perspective on strategic M&amp;A for the last four years, whatever the question was, the answer was no. Now, whatever the question is, the answer, even if it is very, very significant, is maybe. CEOs like to look forward and do big things. There is a lot of activity, and I just think this is an environment where you are going to see significant activity. I think this could be the biggest M&amp;A year in history. It is going to be a bigger IPO year, with a bunch of these big companies finally deciding they want to come through the pipe.

Being a public company is a horrible thing. I do not recommend it. It is challenging. You just have to be okay with getting sued a lot, all the time. It is funny, we had a company that just went public, and they were like, &quot;We might get sued.&quot; I said, &quot;Of course you are going to get sued. You are public. This is America.&quot; I agree a lot on the M&amp;A front, except for the exception that it is not clear what the FTC's position on these things is yet. Especially on big tech, even on small tech, they have been very, very aggressive. So I think M&amp;A will happen, but it may happen more in the form of IP transactions and that kind of thing than as traditional M&amp;A. I hope not, but that may be the case.

I think there are going to be a lot of IPOs coming out of our world. There are going to be some out of necessity, as companies are growing so fast. We have so many companies that went from zero to over a hundred million dollars in less than a year, some zero to over a billion dollars in less than a year, which we have never seen before. The corollary to that in AI is that leads are not what they once were. For my whole life in technology and for the whole history of software, there was this thing called the mythical man-month, where nine women cannot have a baby in a month. So you cannot just, if you are Google, put a thousand software engineers on a product and wipe out a startup, because you can only build that product with, say, seven or eight people. Once they figured it out, they have got that lead, and you are going to be behind for a long time. That is not true with AI. With AI, if you have data, particularly proprietary data, and you have enough GPUs, you can solve almost any problem. It is magic. But it means that you can throw money at the problem. We have never had that in tech. So I think that is actually going to drive a lot of IPOs because people are going to want to get out and have the capital to continue to compete, because it is really necessary. You do not just have a lead you can sit on. So it is going to be a very exciting year, I think.

You were talking about the FTC earlier. I know you and Mark and Chris are spending a lot more time in DC than you ever have. What are some of the policy agendas you are most focused on, and why do you think this is more important now than it has ever been?

The first one was crypto because we thought then, and we continue to think, crypto is an extremely important technology. It is not just the most profound breakthrough in financial technology that we have seen, but a real breakthrough in how society works. Everything from how property rights work on the internet, what is the right architecture for things where creatives contribute most of the value, what is the right business architecture, what is stakeholder capitalism really—these are all things that get solved with crypto. So we thought it was so important for the advancement of society and to not have us descend into communism and these kinds of things. It got completely banned by the last administration, not through a legal or legislative process, but just through sheer will and what we would call an abuse of power of the government, including techniques like debanking. Our company received Wells Notices, which I have never seen before in a private company. So it was an attack from the government on an industry, a technology industry in this country. We said, &quot;Well, we have got to get in and work on that.&quot; The first thing was the GENIUS Act and the Stablecoin Bill, which passed and is now law, and we are very proud of that.

The second one, which we think is the more important bill, is the CLARITY Act, also known as market structure, which establishes something so necessary for this technology because you have these tokens that can represent a Pokémon card, that can represent a stock certificate, that can represent a dollar. There were no rules to say which one this token is, and the approach of the Biden administration was that everything is a security, to the point where they sued artists for, &quot;Oh, I painted a picture and I made an NFT. Oh, you sold a security.&quot; That is crazy. So this one we are trying to get passed right now, and we have had some drama around it, which I am not going to comment on, but that is a thing.

The second one that is really important is AI. With technologies like the automobile or electricity, people freak out about them because they do have a big impact and are going to change the world. With AI in particular, some of the calls are coming from within inside the house, where people are really trying to scare the population, sometimes to achieve regulatory capture and other things. But if you ban the technology, which some people are calling for, or infringe people's ability to do mathematics, which is something a lot of people are calling for, then I think we are definitely going to lose the AI race to China, which has massive, hundred-year implications.

The key things we are trying to protect are: one, the model is a model. It is a mathematical model. It predicts things. It is not a sentient being. Maybe we will figure out how to do that, we do not know how to do that yet, so it is not sentient. It is just a model. So we are trying to say, &quot;Do not regulate math; regulate the applications of that math.&quot; If somebody uses AI to break into a bank, or steal your money, or make a robot that shoots somebody, then that is illegal. But the technology itself should not be illegal.

Then there is the most pressing one right now: every state wants to have its own set of AI laws, which will basically make it impossible for new companies to innovate because you cannot comply with 50 different laws from 50 different states. So we are trying to get that done. Shortly following that, there is an issue of how copyrights are treated. Can you build a statistical model over copyrighted work, not reproduce the copyrighted work, but just build a model about it so that the software becomes smarter? We think that is very important because China absolutely does not respect copyrights. They do not even respect just copying it, let alone building a statistical model. We are going to have a weaker AI if we cannot train on all the data, cannot train on the complete data. So those are the main things that we are trying to push forward.

Awesome. One of the things that was very evident to me during my time at Goldman was how client-centric the firm was, and I know 1GS was a big focus of yours. I am curious how AI is changing the way you both work internally and how you are delivering better for clients.

The firm's business is serving our clients, and technology has for decades been making productive people more productive. Goldman Sachs is a professional services firm filled with productive people that are very productive, and technology has been changing the way they work, evolving the way they work, making them more consequential, allowing them to expand the scope and footprint of what they impact. This technology is another acceleration of that for sure.

In the simplest form—and this is a broad oversimplification, so please take it as such—there are two things we are focused on. One, we have lots of smart people. These are tools and applications. We are trying to get them into their hands and give them access to models and applications so that they can experiment with them, play with them, and figure out how, on a day-to-day basis as they are executing for clients and doing the things they are doing, they can be more productive, more powerful, and have more impact. We are good at this; we have done this before. Our people are good at it. It takes time, but we know how to do this, and we are doing it. It is really constrained by how we get the best tools, the best models, the best applications, and get them regulatory cleared, because we have to deal with regulatory constraints in everything we touch and do. That is a huge barrier for us. We are just not a company that can say, &quot;Oh, this is great. Let's try it.&quot; We have to have a huge process before we can try anything. But we know how to do that, we are doing that, and that is expanding the productivity of our people, and you see real-time uptake on that that is really accelerating.

The more interesting thing to me as the CEO is that this technology allows us to really look at fundamental operating processes on a massive enterprise and completely reimagine them to automate them and make them more efficient. Not just simply for the benefit of doing them with fewer people or with less costs, but for the benefit of taking some of that savings and giving us more capacity to invest in growth areas of the business where we are constrained. We do not have the ability to just spend as much money as we want and lose as much money as we want. We actually have to be held accountable every year to how much money we spend, how much money we make, and what kind of a return we generate.

Companies generally do not last forever. But interestingly, there are companies that have proven they can last for 10-15 years where the accountability on how you are deploying your capital is put off for a long period of time. We have to look at it every year. So I would say in the last few years, we have been constrained. We spent $6 billion on technology last year. I would have loved to spend eight, but if I spent eight, our returns would have been hundreds of basis points lower, and we could not do that. Now, if we can actually find $2 billion of efficiency around reimagining processes, then I can spend eight and wind up with the same returns. So we laid out a program we called 1GS 3.0, where we picked six specific processes in the firm and said we are going to do the work to really completely reimagine them. We have not put out publicly how that changes the workforce or how much capacity that creates, but it is super significant. It is not that there are only six; these are just the first six. This is one of the reasons why the market is running forward. I think this opportunity is huge, but this is hard. This is hard because you are asking people to take away their empire and do their empire differently. It has got to be driven top-down, and it is hard, but we are going to make a lot of progress. So those are two simplifications, but those are two big things I like to summarize.

Anything you would add, Ben, just where do you see the proliferation of this technology in the enterprise and what are you most optimistic for in the next 5 to 10 years?

I think that for the reasons David cited, we are at the very beginning in the enterprise. Changing people and processes in a big existing company is complicated, no matter what the technology is. In our firm, as you know, we are taking a very aggressive approach to first automating all the things people do not like to do or that are not the funnest part of the job. We have also gotten all of our data into a Databricks data lake, so we can ask basically any question about the firm or the portfolio. Customer support for it works fantastically.

AI-centric investing is going to be very, very interesting because models work on the facts that are available, and one of the things about investing is that sometimes the biggest changes in the way you have to think about investing a portfolio come from things that are completely new and unexpected. It cannot be incorporated in a model; it cannot be something from the past. Once it happens, it can be quickly incorporated into models, and models can load very quickly, but still, you start from a place. I am really interested to see how it works, and you have to wonder why a handful of people have so outperformed as investors over a long period of time, but many people underperform. If the models are based on the information that the underperforming people all have, it is going to be interesting to see whether something different comes out of it.

Awesome. I think we are running out of time, but maybe one last bonus question. Favorite DJ? No self-nominations.

Favorite DJ today? John Summit. I mean, John Summit is doing really cool things as a DJ. He is an incredibly interesting young guy that has a lot of energy, and he is evolving very much the context of how big club house DJs do what they do. I think he is doing a great job.

Ben, I am going to stay in my lane, which is the past and hip-hop DJs. I am going to say DJ Jazzy Jeff, who is very underrated because his partner, the Fresh Prince, became Will Smith. But DJ Jazzy Jeff is a great all-time DJ.

Awesome. Thank you guys so much for doing this. Thank you, David. Awesome.
                    </div>
                </div>
                
            </article>
            
        </main>

        <footer>
            Generated by Follower Tool
        </footer>
    </div>
    <script>
        function toggleSummary(id) {
            const preview = document.getElementById('preview-' + id);
            const full = document.getElementById('full-' + id);
            const btn = document.getElementById('sum-btn-' + id);

            if (full.classList.contains('expanded')) {
                full.classList.remove('expanded');
                preview.style.display = 'block';
                btn.classList.remove('expanded');
                btn.innerHTML = 'Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>';
            } else {
                full.classList.add('expanded');
                preview.style.display = 'none';
                btn.classList.add('expanded');
                btn.innerHTML = 'Show less <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>';
            }
        }

        function toggleTranscript(id) {
            const content = document.getElementById('transcript-' + id);
            const btn = document.getElementById('trans-btn-' + id);

            if (content.classList.contains('expanded')) {
                content.classList.remove('expanded');
                btn.textContent = 'View transcript';
            } else {
                content.classList.add('expanded');
                btn.textContent = 'Hide transcript';
            }
        }
        </script>
</body>
</html>